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2 
Abstract 
Influenza A viruses (IAVs) are significant pathogens of humans and animals whose 
main natural host is considered to be wild waterfowl. IAVs have jumped the 
species barrier on multiple occasions, sometimes with devastating 
consequences. Successful infection and onward transmission (i.e. viral 
emergence) requires highly specific interactions between virus and host 
proteins. However, how an avian virus adapts to a mammalian host to establish 
as a novel pathogen after initial interspecies transmission is not yet clear.  
It was hypothesized that adaptation of an avian virus to mammals would involve 
changes in virus-host interactions that would result in more efficient viral 
replication and counteraction of immune responses. To test this hypothesis this 
thesis firstly describes the characterization of an equine dermal cell line 
(E.Derm) for the study of infection with EIVs. A panel of H3N8 AIVs was selected 
to investigate how equine host barriers affect the replication kinetics of distinct 
viruses. Finally, the transcriptome of the equine cells was investigated after 
infection with two evolutionary distinct H3N8 equine influenza viruses (H3N8 
EIVs), and treatment with interferon-alpha (IFN-α). H3N8 EIV is an avian-origin 
virus that emerged in 1960s and has been circulating in horses for over 50 years, 
thus providing a natural model system to study the interspecies transmission and 
post-transfer adaptation of an avian influenza virus to a mammalian host. 
To examine the cellular response to infection, equine dermal cells (E.Derm) 
were infected with either A/equine/Uruguay/63 or A/equine/Ohio/2003. Total 
RNA was extracted at 4 and 24 hours post-infection for RNA sequencing and 
downstream transcriptomics analysis. Mock-infected cells and interferon-treated 
cells were also included for comparison purposes.  RNA-seq data were analysed 
using CuffDiff2 to identify differentially expressed (DE) genes between samples. 
Ingenuity Pathway Analysis was used to determine the intracellular pathways in 
which DE genes were involved. The results showed clear differences on the 
intracellular pathways affected between the viruses, which were especially 
evident during the eclipse phase of virus replication. Distinct intracellular 
pathways were identified as important for EIV adaptation to the horse, which in 
turn could be employed by other avian influenza viruses to establish in 
mammals.  
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1.1. Influenza A virus 
There are three Influenza viruses that make up the Orthomyxoviridae family – A, 
B and C (classified based on the nucleoprotein and matrix segments). These 
viruses are enveloped, segmented, negative stranded with single-sense RNA 
genomes. The term Orthomyxoviridae actually comes from the word orthos, 
which means “standard, correct,” and myxa, which means “mucus” (Cheung & 
Poon 2007).  
 
Influenza was first identified as being the infectious agent of human 
influenza pandemics in 1933 (Smith et al. 1933), and has since continued to be a 
significant cause of disease within the human population. There are four types of 
influenza viruses – A, B, C and D. Influenza D virus was recently identified in 
2011, and is found to infect sheep and cattle (Hause et al. 2014). Influenza B 
and C viruses primarily infect humans, but it is influenza A viruses (IAV) that are 
the most ubiquitous within both human and animal populations, and cause the 
more significant disease. This thesis will concentrate on IAVs and their 
interactions within one host in particular. 
 
IAVs naturally find their hosts in wild birds, such as gulls and waterfowl and 
are the reservoir where most IAVs are thought to have emerged from. They are 
ubiquitously found in those populations, but often are non-pathogenic, meaning 
that they do not cause disease. In birds, IAVs normally replicate in cells lining 
the intestinal tract, and are excreted in high doses in faeces. This offers a 
source of infectivity to other animals via faecal pollution of water. Avian IAVs 
(AIVs) have evolved the ability to jump species barriers to infect mammals such 
as pigs, chickens, seals, whales, horses and humans (Figure 1). 
 
IAVs are one of the most significant respiratory pathogens found in humans. 
There have been four major pandemics within the last 100 years, including the 
1918 “Spanish flu”, an H1N1 virus that is estimated to have led to the loss of as 
many as 50 million lives (Johnson & Mueller 2002), the 1957 H2N2 influenza, the 
1968 Hong Kong H3N2 virus and, most recently, the H1N1 of swine-origin of 2009 
(Morens & Fauci 2007). In conjunction with these pandemic strains, there are 
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always seasonal strains circulating within the human population, which currently 
are H3N2 and H1N1 subtypes. These influenza epidemics arise annually, 
occurring globally during the autumn and winter seasons for each region. One of 
the reasons that make IAVs such important pathogens is their ability to evade 
the host immune response to infection (Hay et al. 2001). This distinctive ability 
allows IAVs to cause pandemics as they are able to expand their host range and 
have much greater antigenic diversity. These influenza viruses are constantly 
undergoing antigenic shift and antigenic drift (explained in more detail later), 
and therefore require new vaccines every year (Salk & Suriano 1949; Kilbourne 
et al. 2002).  
 
 
Figure 1: Schematic representation of IAV host range. 
 
 The antigenic differences within the glycoproteins Haemagglutinin (HA) 
and Neuraminidase (NA) of IAVs are used to classify them into subtypes. There 
have been 18 different haemagglutinin subtypes (H1-H18) documented, and 11 
different neuraminidase subtypes (N1-N11) (Tong et al. 2013). Within the viruses 
that have sustained transmission within humans, only three HA (H1, H2 and H3) 
and two NA subtypes (N1 and N2) have been documented (Bouvier & Palese 
2008).  Avian influenza strains have been transmitted to humans on multiple 
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occasions, such as H5N1, H9N2 and H7N9 (Subbarao & Katz 2000; Gao et al. 
2013).  
 
1.2. Equine Influenza 
It is believed that horses have been infected with Equine influenza viruses (EIV) 
for centuries, with the first EIV being isolated in 1956 of the H7N7 subtype. 
Consequently another H3N8 subtype crossed the species barrier from birds and 
was isolated in 1963.  This new subtype became an established infection in 
horses, and within the next 15 years replaced the H7N7 subtype that had 
previously been circulating. The H7N7 EIV subtype is now assumed to be extinct 
among current horse populations as it has not been isolated since 1977, meaning 
H3N8 is the now the only circulating EIV within horses (Murcia et al. 2010). It is 
this H3N8 EIV that subsequently jumped the host species barrier and infected 
dogs (Daly et al. 2008; Payungporn et al. 2008).  This phenomenon was recorded 
in the early 2000’s, and was shown to be a whole virus jumping from horses to 
dogs. 
 
 There has been another documented incident of horses becoming infected 
with an H3N8 EIV (A/equine/Jilin/1/89). This outbreak occurred in 1989 in the 
Jilin and Heilongjiang provinces of Northeast China, with a high morbidity of 
81%, and the mortality was as high as 20% in some herds (Guo et al. 1995). 
Another outbreak occurred in the following year of 1990 in Heilongjiang province 
with, 41% morbidity and no mortality. The viruses responsible for this outbreak 
were shown to be antigenically distinguishable from the circulating H3N8 
subtype, and in fact the majority of the genes were shown to be of avian origin 
(Guo et al. 1992). 
 
 After much investment into vaccinating horses for EIV, it is still a virus 
that circulates globally and is constantly undergoing antigenic drift (discussed 
later in this chapter), meaning that the vaccine needs to constantly be updated. 
Therefore, this is a virus of importance due to the economic loss of racehorses 
not being able to perform when they are sick. The horse is also a good model to 
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investigate IAV evolution over time in a host, as the virus has been isolated since 
the beginning of the outbreak until present day. 
 
  
1.3. Canine Influenza 
The emergence of Canine Influenza Virus (CIV) dates back to 2004, when the 
virus was first isolated in racing dogs in Florida, US. This virus was shown to be 
an H3N8 EIV virus that had jumped the species barrier from racing horses to 
infect greyhounds (Crawford et al. 2005; Daly et al. 2008; Murcia et al. 2011). 
 
The virus was shown to have a greater than 96% sequence identity with EIV 
and each of the eight segments were of equine origin, showing that the 
emergence of CIV had occurred as a result of direct transmission of the whole 
virus from horses to dogs, with no intermediate reassortment with other strains. 
The new CIV H3N8 continued to circulate in greyhounds and eventually spread to 
pet dogs mainly in shelters.  H3N8 influenza virus has been also reported in 
Australia and the UK (Payungporn et al. 2008; Harder & Vahlenkamp 2010). 
 
Transmission of a whole avian virus to a novel mammalian host is a rare 
event due to host species barriers. These include cell receptors for entry, the    
intracellular machinery necessary to replicate and spread successfully within 
host tissue, environmental barriers and host behaviour preventing contact 
between the two species (Kuiken et al. 2006). These barriers were overcome in 
2006 when in South Korea an avian-origin IAV was first reported in dogs, which 
led to an outbreak in a small animal clinic that eventually showed 100% of 
animals to be seropositive for H3N2 (Song et al. 2008). This virus was 
experimentally shown to transmit to dogs that were contact-exposed to an 
infected H3N2 dog (Song et al., 2009). Four strains of avian-origin H3N2 CIV have 
now been shown to be prevalent in Southern China (Li et al. 2010) and recently a 
high seroprevalence of H3N2 was reported among dogs in North-eastern China 
(Su et al. 2013) 
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1.4.  Structure of Influenza A Virus 
Influenza A virions typically are 80-160 nm in diameter, with a genome that is 
around 13 kb in size. The genome exists as eight single-stranded negative-sense 
RNA segments that are encapsidated into ribonucleoproteins (RNPs), which 
consist of the viral RNA polymerase complex (PB1, PB2 and PA) and multiple 
copies of the viral nucleoprotein (NP). Each segment is numbered one through 
to eight depending upon its length (Noda et al. 2006). This genome encodes for 
at least 20 proteins that are currently known of (Pleschka 2013). The virion is 
composed of an outer lipid envelope that is formed from the host plasma 
membrane as the new virion exits the cell. Across the surface of the virion 
there are two glycoproteins: Haemagglutinin (HA) and Neuraminidase (NA), 
which are found in a ratio of approximately four to one (Lamb & Krug 2001). 
The membrane protein M2 is implanted within the lipid bi-layer, and the matrix 
protein (M1) is found underneath this layer and acts as a structural support for 
the virion. The M1 does this by interacting with the cytoplasmic tails of the 
glycoproteins in the plasma membrane, as well as the NP of the RNP (Rossman 
& Lamb 2011). 
 
The proteins encoded by each of the segments are as follows: Segment 1 
produces PB2 and PB2-S1 (encoded by a novel spliced mRNA (Yamayoshi et al. 
2016)) ; Segment 2 encodes for PB1 but also has alternate open reading frames  
(ORFs) for the expression of PB1-F2 and PB1-N40; Segment 3 encodes for PA, 
PA-X (which has an alternative reading frame to PA) (Jagger et al. 2012), PA-
N155 and PA-N182 produced by leaky ribosomal scanning and initiation from the 
11th and 13th start codons, respectively; Segment 4 is HA, Segment 5 is NP; 
Segment 6 is NA; Segment 7 can undergo alternative splicing for protein 
expression and encode for five proteins M1, M2, M3, M4 and M42 (Jackson & 
Lamb 2008; Helen M. Wise et al. 2009); and finally Segment 8 contains two 
negative-sense ORFs encoding viral proteins NS1 and NEP, a novel donor splice 
site in NS1 which produces a novel influenza A viral protein NS3 (Selman et al. 
2012), and an additional ORF in the positive-sense orientation that encodes a 
negative-sense protein (NSP/NEG8). However, all of these proteins are not 
expressed in all IAV strains (H. M. Wise et al. 2009). See Figure 2 for virus 
structure.  
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Table 1: Summary of influenza A proteins (adapted from Pleschka 2013) 
Segment Number Protein Function 
Segment 1 Polymerase Basic 
2 (PB2) 
Cap-binding subunit of the viral 
RdRp; cap-binding 
Segment 2 Polymerase Basic 
1 (PB1) 
Central location of the 
polymerase domain of the viral 
RdRp 
PB1-F2 Pro-apoptotic activity 
PB1-N40 Undefined 
Segment 3 Polymerase 
Acidic (PA) 
Cap-snatching endonuclease 
subunit of the viral RdRp 
PA-X Endonuclease, cap-snatching 
PA-N155 Undefined, likely important in 
the replication cycle 
PA-N182 Undefined,  likely important in 
the replication cycle 
Segment 4 Haemagglutinin 
(HA) 
Surface glycoprotein, receptor 
binding, membrane fusion, 
antigenic determinant 
Segment 5 Nucleoprotein 
(NP) 
Encapsidation of viral genomic 
and anti-genomic RNA 
Segment 6 Neuraminidase 
(NA) 
Surface glycoprotein, receptor 
destroying Neuraminidase 
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activity, antigenic determinant 
Segment 7 Matrix 1 (M1) Matrix protein 
Matrix 2 (M2) Ion channel activity, protecting 
HA conformation 
Matrix 3 (M3) Undefined 
Matrix 4 (M4) Undefined 
M42 Can functionally replace M2, 
differences in intracellular 
localisation 
 
Segment 8 Non-Structural 1 
(NS1) 
Regulation of viral RdRp activity 
Interferon antagonist; Enhancer 
of viral mRNA translation; 
inhibition of (i) pre-mRNA 
splicing, (ii) cellular 
mRNApolyadenylation, (iii) PKR 
activity, 
Nuclear Export 
Protein (NEP), 
also referred to 
as NS2 
Nuclear export factor 
Non-Structural 3 
(NS3) 
Provides replicative gain-of-
function 
 
Negative Sense 
Protein 
(NSP/NEG8) 
Undefined 
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Figure 2: Influenza A virus structure. NS1 is not included in image, but may be a structural 
protein. (Source: ViralZone:www.expasy.org/viralzone, SIB Swiss Institute of Bioinformatic). 
 
Influenza is a pleomorphic virus, meaning that it can either present itself 
in long filaments or small spherical particles. The functional explanation for 
both forms has not been discovered but filaments are usually observed for virus 
taken from clinical samples, whereas the spherical morphology is observed for 
virus of influenza strains that have been passaged in the laboratory (Choppin et 
al. 1960). The fact that filamentous influenza seems to be selected for in 
nature, but reverts to spherical or ovoid particles when passaged in culture 
suggests that filamentous forms have an advantage and are selected for. A 
recent paper (Seladi-Schulman et al. 2013) compared the serial passaging of 
filamentous virions, in both eggs and MDCK cells, with the spherical laboratory 
strain A/PR8/8/34 (PR8)  in guinea pigs. They showed that the passaging of 
filamentous virus in culture led to a loss of filaments, while the virus serially 
passaged in guinea pigs resulted in a selection of the filamentous form.  These 
findings imply that filamentous variants have a selective advantage in nature.  
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1.5. Influenza A virus replication 
The IAV life cycle begins when the virus particles first bind to the apical surface 
of the target epithelial cells (Figure 3). This interaction occurs between the HA 
glycoprotein spike on the surface of the virus, and specific N-acetylneuraminic 
(sialic) acid residues found on the cell membrane (Whittaker & Digard 2006). 
Depending upon the virus these can either be α-2,3- or α-2,6-linkages (Cheung & 
Poon 2007; Bouvier & Palese 2008). AIVs preferentially bind to α-2,3-linkages, 
and for birds such as ducks and wild waterfowl, these are predominantly found 
in the gut epithelium. For human IAVs, the more commonly preferred linkages 
are α-2,6, which are found in the respiratory tract. However, α-2,3-linkages are 
present in the lower respiratory tract, meaning that if a human does get 
infected with an AIV the infection can be much more severe (Lee & Saif 2009; 
Neumann et al. 2009). Pigs are referred to as “mixing vessels”, as the trachea of 
a pig contains both α-2,3 and α-2,6-linked sialic acids, meaning that there is a 
possibility they could be co-infected by human and avian IAVs potentially 
allowing for virus reassortment (Ito et al. 1998; Wright et al. 2007).  
 
After the virus binds to the cell, the virus particle is internalised by 
receptor-mediated endocytosis (Figure 3). The resulting endosome has an 
increasingly low pH environment due to regulation by proton pumps. The HA 
glycoprotein undergoes a conformational change when it reaches a low enough 
pH. This change allows the fusion peptide to mediate the fusing of the 
endosomal membrane and viral envelope. At the same time the ion channel 
activity by M2, manages the flow of protons into the virion from the endosome 
to lower the pH (Pinto et al. 1992). This acidification of the inside of the virion 
disrupts the protein:protein interactions of the RNPs and M1, and at the same 
time disrupting the interaction of HA and M1. The dissociation of the proteins is 
what causes the passage of the RNPs into the cytoplasm (Lamb & Pinto 2006). 
The NP nuclear localization signal promotes the import of the vRNPs into the 
nucleus, which would have been inhibited by M1, and so dissociation from M1 is 
important. The RNPs are imported into the nucleus through the nuclear pore 
complexes, which is promoted by the nuclear localization signal (NLS) of NP.  
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Unusually, the synthesis of influenza virus RNA takes place in the nucleus 
of an infected cell. This nucleus-based synthesis is rare for most RNA viruses. An 
explanation for it could be that for viral mRNA synthesis, IAVs require the 
capped 5' ends of host mRNAs to act as primers to initiate viral mRNA synthesis 
(Plotch et al. 1981). However, Bunyaviridae are also RNA viruses with 
segmented, negative sense genomes, yet replicate in the cytoplasm. The reason 
for this is that they do not generate spliced mRNAs, unlike Orthomixoviridae 
that require localisation in the nucleus to facilitate splicing (Guu et al. 2012).  
 
Viral replication involves three different types of viral RNAs: viral mRNA 
(mRNA), viral genomic RNA (vRNA), and complementary RNA (cRNA). The initial 
RNA is used as a template to produce complementary positive-sense cRNA and 
negative-sense vRNA. The negative-sense vRNA is used as a template to 
synthesize the cRNA, and from this the RNA polymerase transcribes negative-
sense genomic vRNA. 
 
The viral ribonucleoprotein (vRNP) is comprised of a core of NP copies, 
around which the vRNA is helically wrapped. Each vRNP is also made up of a 
heterotrimeric RNA polymerase complex, consisting of PB1, PB2 and PA. The 
synthesis of viral RNA is carried out by the RNP, which is made up of the four 
viral proteins PB2, PB1, PA and NP (Portela & Digard 2002).  The viral RNA 
(vRNA) is transcribed to mRNA via the RNP, together with the acquisition of a 5’ 
capped RNA that is snatched from the host (Plotch & Krug 1977). During mRNA 
synthesis, the polymerase binds to the 5' end of the vRNA segment and so 
induces the cap-snatching activity of PB2. This cap-snatching activity happens as 
the viral polymerase binds to host mRNAs, which triggers cleavage of the of the 
host mRNAs allowing for the retention of the 5’ host cap structure (Li et al., 
2001). The snatched host cap performs as a primer for the initiation of viral 
transcription, which is mediated by the viral polymerases, more specifically the 
interaction of PB2 with the host cap structure, and elongation of the RNA by PB1 
(Elton et al., 2006).  
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The vRNPs are formed in the nucleus from the newly synthesised proteins 
and are transported into the cytoplasm. The vRNPs are exported out of the 
nucleus through the nuclear pores by the formation of a vRNP-M1 complex. The 
mRNA transcripts must be trafficked from the nucleus to the cytoplasm for 
translation into proteins by ribosomes. However, the segments that require 
splicing to produce more than one protein, for example NS1 and NEP, must be 
spliced before exiting the nucleus.  
 
The encapsidation of the vRNPs is controlled by discrete packaging 
signals, and it has been revealed through electron microscopy that the segments 
are selectively incorporated into each budding particle as seven segments always 
surround one central segment (Noda et al. 2006). A new viral particle must 
contain all eight genome segments to be infectious.  
 
HA, NA and M2 proteins are targeted to the plasma membrane, with HA 
and NA being incorporated into lipid raft structures on the cell membrane. Virus 
budding from these rafts means that the new virions contain HA and NA surface 
glycoproteins. The viral budding is initiated by M1 accumulating in the cytoplasm 
of the cell membrane via association with the tails of HA and NA. 
 
After the viral replication is finished, the virus must exit the host cell. It 
does this through budding from the cellular membrane (Figure 3) by using lipid 
raft domains in the plasma membrane of infected cells. These are sites of virus 
assembly and budding, and are intrinsically linked to the glycoproteins HA and 
NA. The role of NA is very important in that it facilitates the cleavage of the 
sialic acids on the surface of the cell. Without the action of NA the budding 
viruses would stick to the infected cells, and each other, and wouldn’t 
successfully infect neighbouring cells. The anti-influenza drug oseltamivir acts as 
a neuraminidase inhibitor and blocks this action, decreasing virus replication 
efficiency. 
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Figure 3: Life Cycle of Influenza A Virus. Adapted with permission (21). 
 
1.6. NS1 protein and immune response 
The non-structural protein 1 (NS1) of IAVs is not a structural component of the 
virion, as its name suggests (Marc 2014). It is expressed in high quantities in 
infected cells, and is a virulence factor with many different functions. NS1 acts 
by suppressing the host immune response (Lu et al. 1995; Krug et al. 2003) 
regulating viral RNA synthesis, and enhancing viral mRNA translation. Although 
NS1 is the main antagonist of the IFN response, studies have shown that other 
parts of the IAV genome also contribute to this function (Weber-Gerlach & 
Weber 2016).   
 
The NS1 protein is ~26 kDa, and depending upon the strain of IAV the 
majority have a length varying from 230-237 amino acids, some, which will be 
discussed in more detail shortly, are shorter than this (Lamb & Krug 2001). For 
the other influenza A viral proteins (PB1, PB2, PA, NP, M, HA and NA), there isn’t 
much difference between the charge for these proteins among different strains. 
However, avian and human NS1 proteins have different charges, with AIV NS1s 
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being principally acidic, whereas human NS1s are usually basic (Petri et al. 
1982).  
 
The structure of NS1 is composed of two structural domains: the N-
terminal RNA-binding domain (residues 1–73) and the C-terminal effector domain 
(ED) (residues 74–230). The RNA-binding domain is involved in the inhibition of 
IFN induction, and its antiviral effects. The C-terminal contains a PDZ domain 
ligand while the ED controls interactions with host-cell proteins. The final 25 
residues form a “disordered tail (Hale, Barclay, et al. 2008). 
 
The NS1 is almost indispensable to the virus, as it has been shown that 
replication is greatly reduced when mutations are introduced into the NS1 gene, 
and this is especially apparent if these affect the RNA binding domain (Krug et 
al. 2003). The expression of NS1 by itself appears to have a negative affect on 
the host cell, which has been shown when trying to establish cell lines that 
constitutively express NS1 (van Wielink et al. 2011). However, NS1 also acts in 
very specific ways. The host IFN response is antagonised by NS1, through 
inhibition of the antiviral defences of infected cells. NS1 functions by limiting 
both the production and downstream effects of IFN. It does this by first 
preventing the activation of RIG-I, which would usually begin the cascade of the 
antiviral response after being activated by the presence of dsRNA (Randall & 
Goodbourn 2008). It also blocks the RIG-I signal transduction pathway by 
interacting with TRIM-25 and inhibiting RIG-I ubiquitination (Gack et al. 2010). 
NS1 also affects another important constituent of the immune response, protein 
kinase R (PKR), by preventing its activation (Gale & Katze 1998). These 
mechanisms lead to failings in the activation of the IFN system, which in turn 
prevents transcription factors such as NFkB and the family of IFN regulatory 
factors (IRFs) being translocated to the nucleus (Ulfert et al. 2014). NS1 has also 
been shown to limit IFN-β by inhibiting the post-transcriptional processing of 
cellular pre-mRNAs. This inhibition occurs through the binding of NS1 to the 
30kDa subunit of cleavage and polyadenylation specificity factor (CPSF30), which 
stops cellular proteins from binding pre-mRNAs (Kochs et al. 2007). The binding 
of pre-mRNAs inhibits the correct cleavage and polyadenylation of the host 
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mRNAs. The pre-mRNAs can also be retained in the nucleus and can rapidly 
degrade, a process also controlled by NS1 (Katze & Krug 1984). 
 
The other way that NS1 is able to antagonise the IFN response is through 
downstream action, by directly inhibiting the effects of the activated IFN 
system. NS1 sequesters the viral dsRNAs, which prevents the activation of the 
antiviral defences in the cell. The NS1 protein also has a role to play in the host 
apoptotic response to infection. IAVs induce cell death in two ways: by apoptosis 
and, depending on the cell type, by necrosis. Apoptosis can be triggered in 
infected cells by intrinsic responses within the cell, however neighbouring 
uninfected cells are also induced into a state of apoptosis. It is regarded that 
apoptosis is part of the antiviral defence to infection with a virus, as it prevents 
virus replication within the host cells. However, the role of apoptosis in IAV 
replication is complicated, as some pro-apoptotic molecules have been shown to 
allow for the replication of IAVs (Wurzer et al. 2003). It may that the virus 
requires a balance of the pro-apoptotic signals. If apoptosis occurs early during 
virus replication this may stop virus replication, however apoptosis later within 
the cycle may actually benefit the virus by clearing infected cells that would 
stimulate the host adaptive immune response. NS1 has been shown to both 
promote and prevent apoptosis, and may differ depending on viral strain. 
However, NS1 has been shown to interact with the phosphoinositide 3-kinase 
(PI3K) signalling pathway and delay apoptosis induced by viral infection (Hale et 
al. 2006). 
 
The NS1 protein is most often composed of 230 amino acids, however 
there are viruses that exist as shorter or longer than this (Hale, Randall, et al. 
2008). For example, the NS1 of the pandemic H1N1 of 2009, has only 219 aa, 
whereas the NS1 of human IAVS from the late 1940s until the mid-1980s had an 
additional 7 aa. The NS1 of EIVs has been shown to evolve over time during 
replication in its equine host (Barba & Daly 2016). One of the significant changes 
that occurred to EIV during its adaptation to the horse was the introduction of a 
stop codon, which introduced an 11 amino acid truncation in NS1. This 
truncation occurs in the C-terminal region, and leads to viral attenuation due to 
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lack of ability to block host gene expression, which allows for the presence of 
higher levels of type I IFN (Kochs et al. 2009; Solórzano et al. 2005). When 
looking at the early H3N8 CIV viruses, they had a truncated NS1, which is 
understandable as they were directly descent from the EIVs circulating at the 
same time. However, since 2005 all H3N8 CIV viruses have been shown to possess 
the full-length NS1 (Rivailler et al. 2010). The evolution of the canine NS1 may 
be as a direct result of the virus adapting to a new mammalian host. 
 
1.7. Virus evolution 
Influenza A viruses are viruses that can evolve rapidly due to the error prone 
RNA polymerase. Within wild aquatic birds, which is their natural reservoir, 
there doesn’t seem to be such rapid evolution and in fact what could be termed 
as static  (Robert G Webster et al. 1992). However, as an IAV infects a new host 
it will encounter host antibodies that target the surface glycoproteins. This can 
drive amino acid changes to the antigenic sites present within HA and NA (Wright 
et al. 2007). The accumulation of these point mutations leads to a process 
known as antigenic drift.  
 
Antigenic drift happens due to the lack of proof reading by the RNA 
polymerase of the virus, leading to mutations such as substitutions, deletions 
and insertions (Robert G Webster et al. 1992). If these point mutations occur and 
affect the antigenic sites of the virus, they can eventually lead to the virus 
evolving until it cannot be recognised by the host immune response. This 
antigenic drift is the reason that the seasonal influenza vaccine needs to be 
constantly surveyed and updated. Historically, the influenza vaccine was a 
trivalent vaccine against the H3N2 and H1N1 influenza A subtypes, and an 
influenza B subtype. However, since 2012 a quadrivalent vaccine has been 
available that covers an extra influenza B subtype. The rationale behind this 
change was that with the inclusion of only one influenza B subtype, meant that 
people were left exposed to (Ambrose & Levin 2012).  
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Antigenic shift happens when reassortment occurs, due to the segmented 
nature of IAVs. When a single cell is infected with more than one type of IAV, 
the segments can assemble to produce a new virion during viral replication. The 
resulting virus consists of a mixture of genetic information from both parental 
viruses, and can expose a host to antigenic proteins for which there may be no 
pre-existing immunity. In the recent swine H1N1 pandemic virus, this is what 
occurred. Pigs, which are commonly referred to as “mixing vessels” due to the 
presence of both α-2,3 and α-2,6-linked sialic acids, are believed to have been 
the source of the swine pandemic H1N1 outbreak of 2009 when two viruses 
reassorted and produced a new virus to which the human population was 
antigenically naïve. 
 
1.8. Interferon signaling  
When a cell becomes infected with a virus, a vertebrate host has two 
countermeasures with which to defend itself: the innate and the adaptive 
immune systems. The adaptive immune system is highly specific to infection, 
contrary to the innate immune system that is non-specific. The other difference 
is that the adaptive immune response is much slower and can sometimes take up 
to a week to be effective, whereas the innate immune response can act 
immediately or within a few hours of cells becoming infected with a pathogen 
(Alberts et al. 2014). One of the most important aspects of the innate immune 
response is the interferon (IFN) system, which was first documented in 1957 as a 
substance, likely produced by cells, that interferes with influenza infection 
(Goodbourn et al. 2000; Randall & Goodbourn 2008; Isaacs & Lindenmann 1957).  
There are three types of IFN: type I, II and III, and in humans, type I IFNs include 
IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω to name a few. The roles of IFN-α and IFN-β 
have been shown to be induced in response to viral infections, whereas the 
other type I IFNs are less well known but have been thought to be associated as 
regulators of maternal recognition in pregnancy. It has been known for a long 
time that several genes control IFN-α and IFN-β, but it is still unclear how the 
genes are expressed differentially in separate cell types, and whether they are 
induced by distinct viruses or whether they are functionally specialized. 
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Type II IFN has a single type: IFN-γ, and the type III IFNs consist of three 
types of IFN-λ (Ank et al. 2006). The IFNs are not only responsible for the innate 
immunity, but also the adaptive immune response. The production of these 
cytokines begins when a cell recognizes that it has been infected by a foreign 
pathogen, by Pathogen Associated Molecular Patterns (PAMPs). The cells secrete 
these IFN cytokines, and when they reach other neighbouring cells initiate 
intracellular signaling cascades. The IFNs bind to specific receptors on the cell 
surfaces, which leads to the upregulation of many Interferon Stimulated Genes 
(ISGs) that have antiviral properties. The type III IFN receptor appears to be 
limited in its distribution in tissues (Zhou et al. 2007). Type I and type III IFNs 
lead to the same signaling pathways becoming upregulated, whereas type II IFN 
is different. Type III IFNs and their role remains to be completely established 
and so far there is limited evidence supporting whether they have an essential 
role for host response to infection. The signaling cascade caused by the IFNs 
leads the cells to develop into an antiviral state (Hoffmann et al. 2015). There 
also exists a number of ISGs that can be directly upregulated by viral infection in 
an IFN-independent fashion. This method offers certain protection to the 
primarily infected cells, although this is less effective than the full IFN response.  
 
Some viruses, such as IAVs, consist of an RNA genome, and so host cells 
must consist of a way to discriminate and recognize foreign RNA from host RNA. 
Early studies suggested that IFN was induced by synthetic double-stranded (ds) 
RNAs (such as Poly(I:C)), leading to the conclusion that viral dsRNA could lead to 
the induction of IFN (Marcus & Sekellick, 1977; Marcus, 1983). The recognition of 
viral dsRNA as a host defence mechanism is effective as negative-stranded RNA 
viruses generate dsRNA upon transcription, positive-stranded RNA viruses 
generate dsRNA during replication, and even DNA viruses generate dsRNA as a 
result of convergent transcription. RNA viruses also produce 5′-triphosphorylated 
single-stranded (ss) uncapped RNAs during the replication of their viral genome. 
These PAMPs are detected by pattern recognition receptors (PRRs) as “non-self 
RNA”, for exampled Toll-like receptors (TLRs) and melanoma differentiation-
associated gene-5 (MDA-5) or retinoic acid-inducible gene-I (RIG-I) (Goodbourn 
et al. 2000; Randall & Goodbourn 2008). TLR3, TLR7 and TLR9 are endosomal, 
allowing for the detection of dsRNA during virus endocytosis. The other TLRs are 
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largely found in antigen-presenting cells, such as dendritic cells (Schaefer et al., 
2004). RIG-I and MDA-5 are expressed in many different cell types, and can 
detect many different classes of RNA viruses as short and long dsRNA are 
recognized by each PRR respectively. When a cell is infected with an IAV, MDA-5 
is less important, whereas RIG-I is critical (Kato et al., 2006).  
 
 When RIG-I binds viral RNA this begins a process of activation, leading to 
the turning on of downstream signaling pathways. The N-terminus of RIG-I is 
polyubiquitinated by TRIM25 (tripartite motif-containing protein 25), which is an 
E3 ubiquitin ligase that is necessary for activation (Zeng et al., 2009). When RIG-
I binds to RNA it undergoes a conformational changed that exposes the tandem 
caspase activation and recruitment domains (CARD), which lead to 
multimerization and interaction of the CARD domains of MAVS (mitochondrial 
antiviral signaling protein) (Saito et al., 2007).  This leads to the activation of 
interferon regulatory factor 3 (IRF-3) and nuclear factor κ-lightchain-enhancer of 
activated B cells (NF-κB) and they translocate to the nucleus where they turn on 
the promoter of the IFN-α/β gene to initiate the synthesis of IFN-α/β (Randall & 
Goodbourn 2008). 
 
IFN is also important for inducing a pro-apoptotic state within a target 
cell (Goodbourn et al. 2000) The apoptosis of an infected cell allows for its 
removal and attempts to stop the spread of infection. Viral dsRNA can activate 
genes such as PKR (Gale & Katze 1998), which can affect apoptosis. PKR can be 
involved in apoptosis through the eIF2α-dependent pathways (Scheuner et al. 
2006). However, dsRNA alone can activate apoptosis through the formation of a 
complex that leads to the cleavage of procaspase-8 into its active form. The 
well-known apoptotic p53 gene can also be triggered by IFN, or can also be 
triggered directly by dsRNA or virus infection (Goodbourn et al. 2000). IFNs also 
induce a growth arrest within cells, causing suppression of cell growth. 
 
When IFN binds to a receptor of a cell, a signal is transmitted through the 
membrane and into the cell, setting off a cascade of events. The changes within 
the cellular properties occurs strikingly quickly, and the reason for this is that 
many of the necessary components are already constitutively expressed and so 
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the synthesis of new proteins is not immediately required (Larner et al. 1986). 
All IFNs use the JAK-STAT pathway through which to signal. There are four 
known JAKs, of which three are ubiquitously expressed within the cell. The role 
of the JAKs is to bind receptor chains on the inner side of the membrane and to 
give the receptors stability, enable them to be localized to the cell surface and 
most importantly, they are crucial components of the signaling pathway 
(Ragimbeau et al. 2003). When the IFN receptors are not in the presence of a 
stimulus, the cytoplasmic domain of each chain is attached to a JAK protein in 
its inactive state. When IFN molecules bind with the receptors, the chains are 
brought close together causing the two JAKs to undergo transphosphorylation 
and activation. After activation, JAKs phosphorylate the IFN receptor chains and 
begins binding STAT proteins. Consequently, this leads to phosphorylation of the 
STATs and are released from the receptor. In mammals, there are seven STAT 
proteins that exist. However, it has been shown that STAT1 and STAT2 are the 
most important when it comes to IFN signaling through the receptor complexes. 
Type I and III IFN signaling leads to the phosphorylation of both STAT1 and 
STAT2, with heterodimerization and interaction with IFN regulatory factor (IRF) 
9. Together they form the ISG factor 3 (ISGF3) complex, which translocates to 
the nucleus where it binds IFN-stimulated response elements (ISRE) present in 
the DNA upstream of ISGs and results in the transcription of many type I and 
type III IFN signaling ISGs. Those upregulated ISGs have many different roles, 
with some having direct antiviral activity such as interferon inducible 
transmembrane (IFITM) proteins. These work by inhibiting a virus from entering 
the cell by controlling membrane fluidity. However, some of the ISGs act on the 
IFN signaling pathways themselves and control them by positive or negative 
regulation. IRF3 and IRF7 lead to the induction of more IFN, and results in a 
positive feedback loop. Contrary to these ISGs, there are others that act as 
negative regulators if IFN induction, such as activating signal cointegrator 
complex 3 (ASCC3), which functions to modulate ISG expression in an IRF-3- and 
IRF-7-dependent manner (Li et al. 2013). It is important that there are ISGs 
modulating the IFN response, because an excessive induction of ISGs could 
eventually lead to damage of the host, as is apparent in patients who suffer 
from excessive immune activation, which occurred to some of those infected 
during the 2009 pandemic H1N1 outbreak.  
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1.9. Importance of cell lines 
As IAVs are viruses, they are defined as obligate intracellular parasites, in that 
the requirement of a host cell for replication is essential. As has already been 
discussed in this chapter, there are many intrinsic antiviral defences that a virus 
has to overcome to replicate successfully. For example, viruses must first 
overcome physical barriers such as the presence of mucus within the respiratory 
tract before locating the cells with the correct receptors for virus binding. When 
the virus does enter the host cell, it is then faced with the innate immune 
response, including the production of IFN in response to pathogen invasion. It is 
critical that the virus has a way to antagonise this response to allow for 
replication, and in the case of IAVs the protein that is mainly important for this 
is NS1. The initiation of the IFN response is controlled by PRRs, that can respond 
to low-level infection. Therefore, only cells that comprise of intact antiviral 
pathways are able to respond to infection and mount an antiviral defence. It is 
possible that cells can retain the property of responding to IFN-I, and viruses 
that are potent IFN-I inducers (for example, Sendai virus (SeV), or synthetic 
dsRNA (such as polyinosinic-polycytidylic acid (Poly I:C)) but lose their ability to 
respond to low levels of viral infection. 
 
 It is important that an in vitro cell system should be convenient and 
physiologically representative of the cells infected in vivo (Hare et al. 2016). 
There are different methods to produce a cell line for in vitro studies, including 
using primary cells and immortalised cells. However, both of these methods have 
negative factors. Primary cells can better represent cell from the original tissue, 
because they have not been passaged continually in tissue culture leading to 
mutations and change of phenotype. However, they are a difficult system to 
work with as primary cells are limited in how many times they can be doubled, 
and close to senescence (when cells undergo replicative arrest) by the time the 
selection of the cell population is complete. There are also examples showing 
that cells at later passages produce a higher basal level of IFN-β, and therefore 
produce an unrealistic stronger IFN response when infected with a virus (Reddel 
2010). Therefore, these changes can affect the results when studying virus-host 
interactions, and it makes it crucial to study experiments with cells at the same 
passage so as to account for these changes. Primary cells are also notoriously 
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difficult to transfect, making it difficult for experiments that require exogenous 
gene expression. Therefore, primary cells are problematic to work with and 
another system is usually required. 
 
However, transforming cells leads to a continual culture of cells that don’t 
necessarily resemble the phenotype of the original cell. Tumourigenesis and the 
process of continually culturing cells lead to a collection of mutations that 
change how the virus and host interact. The reason for this is that some of the 
cellular pathways that are involved in antiviral defence and tumour suppression 
are shared. It has been shown that cells that lack antiviral genes are easier to 
immortalise in cell culture, and so immortalisation of cells is often accompanied 
by a loss in response of virus invasion (Chen et al. 2009).  The fact that tumour 
suppression and antiviral defences are linked, also leads to the fact that cells 
that are deficient for tumour suppressors are also more susceptible to virus 
infection (Munoz-Fontela et al. 2005). 
 
The research described in this thesis explains the characterization of an 
equine cell line for the relevant study of influenza infection. It was important to 
find a cell line that was appropriate for the study of EIVs and their interaction 
with an equine host cellular response. MDCKs (Madin-Darby Canine Kidney 
Epithelial Cells) are the most widely used cell type for in vitro experiments with 
IAVs. However, they are not appropriate for studying the virus-host interactions 
for a number of reasons. When MDCKs were first shown to be infected by IAVs, it 
was discovered that they were permissive to infection with a wide range of 
influenza viruses (Gaush & Smith 1968). MDCK cells also require the addition of 
an exogenous protease to facilitate the cleavage of the glycoprotein HA in order 
to produce a mature virion (with the exception of WSN influenza virus). With the 
addition of an exogenous protease, it means that natural host protease barriers 
to infection cannot be investigated (Seitz et al. 2012). Another finding described 
in the literature is that in MDCK cells the IFN response is a weak restrictive 
factor for the replication of IAVs, which is partly caused by a deficiency of anti-
influenza activity by the canine Mx proteins (Seitz et al. 2010). 
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Overall, while MDCK cells are very efficient at growing almost all IAVs, 
and producing very high virus titres, the cell line is not physiologically relevant 
to study host-virus interactions in relation to IAVs. Therefore, when studying the 
host barriers to infection, is it important to select a cell line that best reflects 
the composition of the host organism. Cells must have a preserved innate 
antiviral response, and be sufficiently sensitive to stimuli. One of the chapters in 
this thesis concentrates on characterizing an alternative cell line for the 
investigation of equine host barriers to infection with IAVs. 
 
1.10. Ex-Vivo Organ Culture Systems 
The most commonly used practice in laboratories are in vitro studies that 
attempt to study viral evolution, pathogenesis and the immune responses to the 
host in the artificial context of cells grown in wells. This allows for the discovery 
and research of many new areas but sometimes in vivo studies are necessary to 
provide the full scientific answers required for these questions. However it is 
crucial in the use in vivo studies to justify the use of animals in research and can 
often lead to the criticism from animal welfare groups. 
 
Therefore the majority of experiments occur in vitro, which are not ideal 
models due to absence of cell polarity and pseudostratification of the cell 
layers. This becomes an issue when studying pathogens that infect 
pseudostratified epithelium such as Human Papilloma Virus (HPV) or, as in this 
study, influenza A virus. When studying the influenza infection, which naturally 
infects tracheal tissue, using in vitro methods sometimes means that cilia and 
microvilli can be absent, although they are ndpresent for cells such as MDCKs. A 
major contrast between in vitro and in vivo is that there is no air interface with 
the infected cells. 
 
The other shortcomings of in vitro methods are also that the cell lines 
used have been severely mutated to become “immortalized” cell lines and so 
are abnormal. They may also be cells lines from an entirely different species, 
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not from the host species, and are usually located from a different type of tissue 
than that of which the virus normally infects. 
 
An excellent alternative to these problems with in vitro methods is to use 
an ex vivo organ culture (EVOC) system, which takes the tissue of interest from 
the organism and keeps it as close to natural conditions as possible. These EVOC 
systems allow for the reduction of animals in research, as part of the 3Rs 
framework (Zurlo et al. 1996). In previous studies tracheal explants have been 
used to study swine influenza pathogenesis (Nunes et al. 2010). Each trachea is 
split into many small explants, meaning that numerous experiments can be 
carried out from the one animal, greatly reducing the number of animals used as 
compared to those needed for the same study using in vivo methods. It is also 
important to note that when experiments with pathogens are carried out in vivo 
in animals, the side effects of the infections can be unpleasant, whereas this can 
be avoided through use of EVOC. The variability between animals is also 
decreased as the same animal phenotype can be guaranteed. 
 
The EVOC system therefore is a good alternative, providing the 
compromise between in vitro and in vivo methods, presenting tissue pseudo-
stratification, along with important features like receptors and cilia, to be 
preserved for at least seven days. Another similar system that had been 
previously optimized by Jackson et al. (Jackson et al. 1996) was used to study 
human nasal turbinate tissue with an air interface, was able to keep the nasal 
tissue alive and healthy for 20 days. This was better than previous traditional 
methods that fully immersed the tissue in medium, which interfered with the 
natural processes of infection. These systems, along with many others (Jang et 
al. 2005; Priestnall et al. 2009),  can  be  used  as experimental platforms to 
bridge the gap between in vitro and in vivo methods. This thesis will only briefly 
look at an experiment within the EVOC system, but is worth noting as the future 
work expanding upon this thesis could make use of the system much more 
readily. 
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1.11. Transcriptomics 
There has been a recent increase in the research field of “omics”. This includes 
genomics, proteomics and transcriptomics. There are many positive and negative 
reasons to each technique. For example, proteomics provides a much more 
definite picture of what is happening inside a cell through the study of the 
proteins but is limited due to expense and availability of mass spectrometers. 
Transcriptomics studies the transcripts present within a cell, but that does not 
necessarily mean that these transcripts will be translated into proteins. 
However, as it is more readily available and is a reliable technique, this chapter 
will focus on the use of transcriptomics to study equine cellular pathways. 
 
Transcriptomics used to be carried out most of the time using qPCR. 
However, as it has a limited output it isn’t suitable for genome-wide studies. 
Microarrays followed after qPCR, as it allowed for the expansion to study 
thousands of genes using DNA probes. It is important to note that this can 
produce a more biased result than RNASeq, as the DNA probes can produce a 
level of selection for the genes that the researcher is interested in. On the other 
hand, RNASeq amplifies all of the RNA within a cell, and so allows for a more 
critical analysis of which genes are differentially expressed. 
 
There are a few different tools that can be used for in silica analysis of 
RNASeq data, some of these being edgeR, DeqSeq and CuffDiff2 (Robinson et al. 
2009; Trapnell et al. 2013). Each one runs with a slightly different pipeline, with 
edgeR and DeqSeq using count based methods to measure the level of expression 
of RNA. However, CuffDiff2 uses an alternative method of mapping the RNA-seq 
reads to a reference genome, and then calculates the transcript abundance to 
produce an output defined as: Fragments Per Kilobase of transcript per Million 
mapped reads (FPKM). The FPKM value for the combined replicates of each 
condition is compared to the FPKM value of the Mock-infected cells. This 
comparison allows the calculation of the fold change in the gene expression, 
which is reported as the Log2FoldChange (Log2FC). There should be less false 
positives when using CuffDiff2, as the pipeline controls for cross-replicate 
variability. Each differential expressed gene is given a statistical significance, 
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which allows for the creation of thresholds to decide upon what level of 
expression within the genes that should be studied. Studies have been carried 
out to compare the different pipelines, and depending upon the data available 
some will be more suitable than others (Zhang et al. 2014). However, as this is 
still a relatively novel technique, there is still a lot more research required into 
the different pipelines and how they are beneficial. For the purposes of this 
thesis, the CuffDiff2 pipeline was selected to study the RNASeq data. 
 
1.12. Conclusion 
Influenza A is a complex virus that has managed to evolve so as to overcome the 
species barrier and infect different hosts many times in history. The recent jump 
of EIV from horses to CIV in dogs shows how the virus is still constantly changing. 
The H3N8 subtype is especially interesting as it has managed to cross the host 
species barrier twice to infect horses, and has infected other mammals as well. 
As there was much surveillance of horses before this species jump, there is a 
unique opportunity to study influenza within this context to try and answer the 
questions of the requirements for the virus to infect a new host species. This 
thesis provides the opportunity to study H3N8 IAVs more closely to determine 
how host barriers interact with the viruses upon infection.  
 
1.13. Objectives and Aims of Project 
 
The overall objective of this project is to generate important new information 
on the pathogenesis of different IAVs in an equine host to better understand the 
process of viral emergence. 
 
1. Characterization of an equine cell line for the in vitro study of EIV 
As has been discussed in this chapter, it is essential to use a physiologically 
appropriate, IFN competent cell line when studying the host response to 
infection with a virus. It is also essential that the cell line is relevant to the host 
organism it has come from, and reflects the results seen in nature in vivo. 
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Therefore, one of the aims of this thesis was to find an equine cell line, and fully 
characterize it for the effective study of IAVs, and specifically EIV. 
 
2. Explore equine host barriers to infection with different IAVs 
The reason it was essential to have a relevant equine cell line in which to study 
IAVs, was that one of the primary aims of this thesis was to study how IAVs of 
different origins replicate within an equine host, and what the host barriers to 
infection may be. 
 
3. Determine the cellular response to infection between two evolutionary 
distinct equine influenza viruses of the same lineage using transcriptomics 
Using the new tool of transcriptomics, investigate how two evolutionary distinct 
EIVs (one from the beginning of the EIV H3N8 outbreak, and one after 40 years of 
adaptation to the equine host) differ in the way they control host cellular 
responses to infection.             jjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj
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2.1. Introduction 
Influenza A virus (IAV) is a pathogen that has had a significant impact upon 
human health (World Health Organization 2018).  There have been four major 
pandemics of influenza within the last 100 years, with the 1918 “Spanish flu” 
estimated to have caused 50 million deaths (Johnson & Mueller 2002). Seasonal 
strains of influenza, H3N2 and H1N1 (H for Haemagglutinin, and N for 
Neuraminidase), are constantly circulating, and evolving to escape host 
immunity. These circulating strains necessitate a costly vaccine, which requires 
annual updating to remain effective against antigenic drift and shift (Salk & 
Suriano 1949; Kilbourne et al. 2002). 
 
As discussed in Chapter 1, IAVs have the potential to cross host species 
barriers and infect various hosts such as seals, pigs and humans (Anthony et al. 
2012; Ito et al. 1998; Smith et al. 1933). A cross-species transmission event can 
either be deemed a “spillover” event, or if the virus maintains sustained 
transmission in the new host, an “emergence”. There have been two 
documented subtypes of equine influenza emergence in horses. H7N7 was first 
identified in 1956, and H3N8 was reported in 1963 (Waddell et al. 1963). H7N7 
has not been detected for the past 30 years, and is now thought to be extinct 
(Webster 1993; R G Webster et al. 1992). It is believed the only currently 
circulating equine influenza is of the H3N8 subtype. 
 
Despite the availability of vaccines and investment in preventing 
transmission, H3N8 EIV (Equine Influenza Virus) is still circulating in many 
countries. Due to its high morbidity in horses, outbreaks can have high economic 
costs resulting from poor performance in racing. Therefore the study of its 
pathogenesis, and investigating its prevention, is important. 
 
The lack of exchange of viral genes between EIV and influenza viruses 
from other species (Guo et al. 1991) had led to the assumption that horses were 
a ‘dead-end’ host. However, EIV jumped the species barrier and infected dogs in 
the early 2000’s (Anderson et al. 2012). Canine Influenza Virus (CIV) was first 
isolated in 2004 in Florida, US (Crawford et al. 2005). CIV was shown to have a 
greater than 96% sequence identity with EIV, and each of the eight segments 
were of equine origin. This high sequence identity indicated that the emergence 
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of CIV was a result of direct transmission of the whole virus from horses to dogs, 
with no intermediate reassortment with other strains (Payungporn et al. 2008; 
Harder & Vahlenkamp 2010). Moreover, this is not the only documented case of 
EIV H3N8 inter-species transmission. EIV has been detected in pigs (Tu et al. 
2009) and a Bactrian camel (Yondon et al. 2014). With EIV H3N8 seeming to have 
a high possibility of host expansion, it is important to study this virus to better 
understand IAV host-switching mechanisms and barriers. 
 
There are many issues involved in the experimental study of influenza in 
horses. Apart from the great economic cost, the majority of horses are routinely 
vaccinated against influenza (Murcia et al. 2010), meaning that it is difficult to 
find suitable animals. Another issue is the ethical concern that horses can be 
viewed as companion animals.  Therefore, even though it is of great importance 
to study EIV H3N8, in vivo experiments can prove very challenging. 
 
When thinking about in vitro influenza experiments, the number of 
primary cells and cell lines that are able to maintain influenza virus replication 
is limited. Cell lines such as A549 (human alveolar epithelial), Vero (African 
green monkey kidney), DF-1 (chicken) and MDCK (Madin-Darby Canine Kidney) 
have all been used for the study of influenza (Lee et al. 2010; Kaverin & Webster 
1995; Lee et al. 2008; Gaush & Smith 1968). Overall, MDCK cells are the most 
widely used for influenza isolation and propagation (Gaush & Smith 1968; 
Ilyushina et al. 2012; Gregersen et al. 2011; Audsley & Tannock 2004). However, 
for the successful replication of most influenza viruses in MDCK cells, the 
addition of exogenous trypsin is necessary (Tobita et al. 1975). It is also 
important to remember that MDCK cells are of canine-origin and therefore make 
it difficult to study specific equine host defence mechanisms to infection. A 
review by Hare et al. (Hare et al. 2016) discusses the importance of finding 
physiologically relevant cell lines to study host-virus interactions. 
 
There has previously never been an equine cell line documented in the 
study of EIV. Equine primary respiratory epithelial cell cultures have been 
successfully generated, but have problems such as finite number of cell divisions 
(Lin et al. 2001). Therefore, a continuous equine cell line known as Equine 
Dermal (E.Derm) (Cullinane et al. 1988; Telford et al. 1992) was selected and 
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characterized specifically for the experimental investigation of EIVs. The current 
chapter describes an investigation into the potential susceptibility and 
permissibility of infection with EIV, and establishes if the results were consistent 
with what is observed in vivo. Once characterized the cell line was used for 
transcriptomic studies (described in Chapter 4 & 5). Therefore, it was important 
to assess their competency to produce and respond to interferon.  
 
The aims of work described in this chapter were to find a continuous cell 
line for the study of EIV, characterising optimal infection conditions and 
susceptibility to influenza infection. It was important to determine IFN 
(Interferon) competency, so as to better understand the virus-host interactions 
(Hare et al. 2016). A reverse genetics virus of EIV from 2003 was used as the 
control virus throughout these experiments. 
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2.2. Results 
2.2.1. E.Derm cells are susceptible to infection with equine influenza virus 
To determine whether EIV is able to enter and infect E.Derm cells, monolayer 
cultures of E.Derm cells were first infected with EIV/2003 at a high MOI (MOI 3 
based on MDCK titre). NP expression was determined at 4 hours post-infection, 
and a number of infected cells were observed by a strong fluorescence staining 
in comparison with mock-infections (Figure 4, A). 
 
 
Figure 4: (A) E.Derm cells at 4 hours post-infection with EIV/2003 at an MOI of 3 (based on MDCK 
titre). Nuclei are stained blue, and NP is in green. (Magnification x63) (B) Light microscopy 
images of E.Derm cells Mock- and EIV/2003- infected at 24, 48 and 72 hours post-infection MOI 
0.1 (based on MDCK titre). Horizontal bars represent 1,000 µm. (Magnification x4) 
  
Using a low MOI (0.1 based on MDCK titre) E.Derm cells were infected and any 
changes were observed over 72 hours (Figure 4, B).  Mock-infected cells showed 
almost no changes in morphology, whereas infected cells showed Cytopathic 
B 
Mock EIV/2003 
A 
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Effects (CPE), such as cell shrinkage and rounding. Extensive cell death was not 
observed in infection with EIV/2003. 
 
2.2.2. The eclipse phase of equine influenza in E.Derm cells is 7 hours 
The eclipse phase is the period of time when the virus has entered the cell and 
is undergoing replication, but has not yet completed one cycle and exited the 
cell (White & Cheyne 1966). Researchers have previously reported eclipse times 
of 6 hours (Heldt et al. 2013). To determine the length of time of the eclipse 
phase in E.Derm cells, cell cultures were infected with an MOI of 3 (based on 
MDCK titre) and supernatant was collected every hour, up to 12 hours, and 
titrated. The curve of the graph began to increase after 7 hours of infection and 
it was determined that this was when the virus began exiting the cell (Figure 5, 
A). Furthermore, infected cells were also fluorescently labelled for the 
Haemagglutinin (HA) protein. Immunofluorescent staining of HA could be seen on 
the surface of the cell at 1 hour post-infection and slowly decreasing until 4 
hours post-infection. At 6 hours post-infection HA staining could be observed 
distributed at the cell surface, ready for virus budding. Spherical HA staining 
could be seen on the surface of the cells from 7 hours post-infection (Figure 5, 
B). 
 
It is very important to note that virus titrations throughout this thesis are 
affected by a methodological error, described in more details in the Materials 
and Methods section. Regrettably, it was not possible to repeat these 
experiments in the time available and, because the degree of systematic error 
might vary, the ability to make quantitative comparisons between these data is 
limited. However, it is still possible to describe changes in qualitative terms. 
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Figure 5: (A) Growth kinetics of E.Derm cells infected with EIV/2003 at an MOI of 3 (based on 
MDCK titre). Supernatant was collected every hour and titrated from three independent 
experiments; error bars indicate the standard error of the means. (B) Cells were grown on 
coverslips and infected at the same time as growth curves, fixed and stained. Nuclei are shown 
in blue, HA is in green. (Magnification x100) 
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2.2.3. Infection of E.Derm and MDCK cells with the same inoculation 
produces different percentage of infected cells 
Throughout this thesis, cells will be collected and stained using an anti-NP 
antibody. A Guava Flow Cytometer was used to measure cells using Forward and 
Side Scatter. Live cells were sectioned off, and then of these cells a gate was 
created to quantify the percentage of fluorescently stained cells (Figure 6). 
 
 
Figure 6: Guava Flow Cytometer gating. A Forward Scatter vs Side Scatter density plot was used 
to create a region of live cells (Plot P01). Subsequently these cells were separated into Green 
Fluorescence vs Red Fluorescence, and a gate was adjusted to the background fluorescence of 
the Mock-infected cells, which allowed for the quantification of infected cells (Plot P02). 
 
To assess the entry efficiency of EIV in E.Derm, as compared to MDCK cells, both 
cell lines were infected with EIV/2003 at an MOI of 3 (based on MDCK titre). 
Intracellular virus levels were compared by staining the cells for the NP protein 
to give an indication of the percentage of cells infected (Figure 7). NP-positive 
cells were measured using a Guava Flow Cytometer. A significant difference was 
found, with ~55% of E.Derm cells and ~92% of MDCK cells infected at 4 hours 
post-infection (*). There was also a significant difference (*) between MDCK and 
E.Derm infected cells at 6, 8 and 10 hours post-infection. MDCK cells had a 
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maximum permissiveness of around 90%, whereas E.Derm cells peaked at ~80%. 
The percentage of cells infected became more similar at 12 to 20 hours post-
infection, with a significant difference again at 24 hours post-infection (*).  
 
 
Figure 7: Percentage of NP-positive E.Derm and MDCK cells infected with EIV/2003 (MOI 3, based 
on MDCK titre). Infected cells were measured using the Guava Flow Cytometer. Experiments 
were repeated independently three times; error bars indicate the mean with range of the values. 
A statistical t-test was carried out, comparing the values in the infected E.Derm and MDCK cells. 
Significance is shown with * where p≤0.05. 
 
2.2.4. Equine influenza can replicate in E.Derm cells without the presence of 
exogenous trypsin 
For most influenza viruses replicating in MDCK cells (with the exception of WSN 
(Influenza A/WSN/33) virus), the addition of exogenous trypsin is required for 
multi-cycle infection. This is due to the necessity of a protease to cleave the HA 
of newly produced virions, leading to maturation and ability to infect another 
cell. 
 
When EIV/2003 was grown in MDCK cells without the customary addition of TPCK 
trypsin there was a significant difference (*) at 48h and 72h post-infection 
between the percentage of cells infected with and without the presence of TPCK 
trypsin (respectively 48h: ~62% and ~32%, 72h: ~75% and ~35%) – as determined 
by examining the proportion of infected cells (NP-positive cells counted by FACS) 
(Figure 8, A+B). For the extracellular virus (titrated in the supernatant) titre, 
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there was a difference of around 4 logs at 48h and 5 logs at 72h (Figure 8, A+B). 
 
Figure 8: Growth curves of intracellular and extracellular EIV/2003, with and without the 
addition of exogenous TPCK trypsin in the infection media, in MDCK (A+B) and E.Derm cells 
(C+D). (E) E.Derm cells grown with and without exogenous TPCK trypsin in the media. MDCK cells 
were infected with MOI 0.01 (based on MDCK titre), and E.Derm cells were infected with MOI 0.1 
(based on MDCK titre). Experiments were repeated independently three times; error bars 
indicate the mean with range of the values. For each figure a statistical t-test was carried out, 
comparing the values in the presence and absence of TPCK trypsin. Significance is shown with * 
where p≤0.05. 
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However, when EIV/2003 was grown in E.Derm cells either in the presence or 
absence of TPCK trypsin, no significant difference was found either in 
extracellular virus or intracellular virus (Figure 8, C+D). 
 
The presence of TPCK trypsin appeared to effect E.Derm cells in a negative way, 
as can be seen from major CPE in the Mock-infected cells that contain exogenous 
TPCK in the medium (Figure 8, E). This negative effect was most apparent from 
48 hours, with the rounding and detachment of cells from the culture plate. 
Therefore as TPCK trypsin was not necessary for the multi-cycle growth of 
EIV/2003, and was also harmful to the cells, future experiments were performed 
without its addition.  
 
2.2.5. E.Derm cells are selective in susceptibility and propagation of 
influenza viruses 
As well as investigating the infectivity of E.Derm cells with EIV, their ability to 
be selectively permissive for different influenza viruses was examined. One of 
the disadvantages of using MDCK cells is that they are susceptible to many 
influenza viruses and therefore it is hard to determine host barriers to infection. 
 
To test whether the viruses examined had similar growth kinetics in a non-
selective cell line, MDCK cells were infected with an MOI of 0.01 (based on MDCK 
titre). The growth kinetics were followed over 72 hours, by titrating the 
supernatant and quantifying the number of NP-positive cells using a Guava Flow 
Cytometer. Figure 9 (A+B) shows that when EIV/2003 and CIV/2009 were grown 
in MDCK cells there was no significant difference in the growth kinetics, 
demonstrating that both viruses were able to replicate efficiently in this cell 
line.  
 
It has been shown that EIV jumped species into dogs and evolved to become CIV 
and subsequently lost its ability to infect horses (Yamanaka et al. 2012). To test 
whether this phenotype was replicated in E.Derm cells, the cells were infected 
with both EIV/2003 and CIV/2009 at an MOI of 0.1 (based on MDCK titre), and 
the growth kinetics were observed over 72 hours. As can be seen from Figure 9 
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(C+D), EIV/2003 grew to very high titres, with significant differences to CIV/2009 
at 24 and 48 hours post-infection (*). EIV/2003 peaked at over 109 PFU/ml at 24 
hours. In comparison CIV/2009 grew to titres that were 5 logs lower, to just less 
than 104 PFU/ml at 24 hours. The difference between the ability of EIV/2009 and 
CIV/2009 to infect the E.Derm cells was also evident in the number of NP-
positive cells. There was a significant difference between both viruses at all 
time-points (*). Infection with EIV/2003 peaked with 80% of cells infected at 48 
hours, whereas only 20% of cells were infected with CIV/2009 at 48h. 
 
 
 
Figure 9: Growth kinetics of EIV/2003 and CIV/2009 in MDCK (A+B) and E.Derm (C+D) cells, 
infected with MOI 0.1 (based on MDCK titre). Infected cells were measured using the Guava Flow 
Cytometer. Experiments were repeated independently three times; error bars indicate the mean 
with range of the values. For each figure a statistical t-test was carried out, comparing the 
values in the EIV/2003 and CIV/2009 infected cells. Significance is shown with * where p≤0.05. 
 
2.2.6. E.Derm cells both respond to and produce interferon 
It was necessary to verify whether E.Derm cells were an interferon (IFN) 
competent cell line, i.e. that they were able to both respond to exogenous IFN 
and also produce IFN in response to stimuli. To this end E.Derm cells were 
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treated with increasing concentrations of Universal IFN-α (derived from Human 
IFN-α) for two time-points of treatment (4h and 24h). These cells were then 
challenged with a VSV-ΔG-GFP (a green fluorescent VSV virus lacking a 
glycoprotein, meaning it is replication incompetent) to determine the level of 
protection from infection, measured using a Guava Flow Cytometer. All 
concentrations of IFN-α treatment produced a significant difference (*). The 
protection level increased with the concentration of IFN-α, and there was 
slightly higher protection after pre-treating the cells for 24h (34% and 25% of 
relatively infected cells at 4h and 24h of 1000 UI/ml of IFN-α pre-treatment, 
respectively) (Figure 10, A). 
 
Figure 10: (A) E.Derm cells were treated for 4h and 24h with increasing concentrations of IFN-α 
or Poly I:C, and then challenged with a VSV-ΔG-GFP virus to assess the level of protected cells. 
(B) E.Derm cells treated for 24 hours with 1,000 UI/ml of IFN-α have a higher expression of Mx1 
(in green). Experiments were repeated independently three times; error bars indicate the mean 
with range of the values. A statistical t-test was carried out, comparing the values to no 
treatment. Significance is shown with * where p≤0.05. 
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To determine how well E.Derm cells could produce their own IFN, a similar 
experiment was conducted. Cells were treated with increasing concentrations of 
Poly I:C for two lengths of time (4h and 24h). Poly I:C is a mimic of double-
stranded (ds) RNA (a stimulus of the IFN pathway), and upon exposure the cells 
should produce IFN. To test the antiviral level the cells were challenged with 
VSV-ΔG-GFP infection, protection was measured using a Guava Flow Cytometer. 
The protection increased as the concentration of 4 hours of Poly I:C treatment 
increased, with all treatment concentrations showing a significant difference (*) 
to cells with no treatment. There was a greater difference observed between 4h 
and 24h pre-treatment than was seen for IFN-α pre-treatment (~71% and 17% of 
infected cells at 4h and 24h 10ng/ml Poly I:C pre-treatment, respectively) 
(Figure 10, A). All of the concentrations of Poly I:C produced a highly significant 
(*) difference compared to no treatment with 24 hours of treatment time. 
 
Mx1 (Myxovirus Resistance Protein 1) is a well-characterized interferon-
stimulated gene (ISGs) that has been shown to have antiviral activity against 
influenza (Staeheli et al. 1986). Therefore, the expression of Mx1 in E.Derm cells 
after IFN-α treatment was investigated. As can be seen from Figure 10 (B), Mx1 
was upregulated following pre-treatment with 1000 UI/ml of IFN-α for 24h. 
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2.3. Discussion 
Equine influenza is a significant pathogen of the horse that requires more study, 
as it could shed light on cross-species transmission events. To date, an equine 
cell line has not been described for the in vitro experimental study of EIV. This 
chapter describes the full characterisation of the equine cell line E.Derm, 
derived from the dermis of a horse.  
 
E.Derm cells were shown to be susceptible to infection with EIV, as shown 
by NP fluorescence positive cells after infection with EIV/2003 (Figure 4). When 
the virus was grown over the course of 72 hours, CPE was observed as the 
shrinking and rounding of cells. However, this CPE was not dramatic and 
certainly did not destroy the complete cell monolayer, as is normally observed 
for influenza infection in MDCK cells. This may be due to the existence of host 
barriers, or that the virus infects but does not lead to cell death. 
 
For transcriptomic studies of infected E.Derm cells in Chapter 4, two 
separate time-points were examined. The first time-point was completed during 
the eclipse phase of the virus life cycle; and the next at 24h post-infection, 
when the virus will have undergone several replication cycles. It has been 
documented that one complete influenza replication cycle in MDCK cells takes 8 
hours, which had yet to be characterized for E.Derm cells. To characterise the 
time taken to complete a single replication cycle, cells were infected with a 
high MOI (MOI 3, based on MDCK titre) and supernatant was collected every hour 
to observe when the growth curve began to increase its slope. As demonstrated 
in Figure 5 (A) the slope begins to increase at 7 hours post-infection. 
Accompanying immunofluorescence images show that the viral HA begins to line 
the cell surface, in preparation for virus budding at 6 hours post-infection. At 7 
hours HA, suggestive of virus budding, can be seen. This result was encouraging 
as the eclipse phase was very similar to other cell lines. Based on this 
information future “eclipse phase” time-points were taken at 4 hours post-
infection. 
 
During the characterization of E.Derm cells, the addition of TPCK trypsin 
to the growth media was observed to cause stress to the cells (Figure 8, E). 
TPCK trypsin is normally added in most in vitro influenza infections. It is needed 
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for the cleavage of HA to produce a mature virion and continue the replication 
cycle, which is normally carried out by cellular proteases in vivo (Kuiken et al. 
2006). Decreased concentrations of TPCK trypsin to 0.1 ng/ml still resulted in 
CPE in control cells. Therefore, infections in E.Derm and MDCK were performed 
with and without the addition of TPCK trypsin. Viral growth in MDCK cells was 
inhibited significantly, confirming the requirement to add TPCK trypsin for 
successful replication (Figure 8, A+B). In contrast, the virus was still able to 
replicate in E.Derm cells, to a level only a little lower than with the addition of 
regular infectious media containing TPCK trypsin (Figure 8, C+D). Therefore, all 
further experiments carried out in E.Derm cells were carried out without the 
addition of TPCK trypsin (note, TPCK trypsin was still used in the infectious 
media for 1-hour inoculations so as to cleave any HA in immature virions 
produced in the virus stock grown in MDCKs). The absence of TPCK was 
especially important when investigating transcriptomic responses to infection, as 
stress responses to TPCK trypsin no longer need to be considered (please refer to 
Chapter 4 for transcriptomics work). 
 
When E.Derm cells were infected with the same MOI (based on MDCK 
titre) as MDCK cells, they had a lower percentage of cells infected (Figure 7). 
There could be other factors involved in E.Derm cells, such as host barriers that 
are not present in MDCK cells. The interferon response of MDCK cells may well 
be inhibited after continual culturing (Masters & Stacey 2007). Canine Mx in 
MDCKs has been shown to be deficient (Seitz et al. 2010), which may explain 
why influenza viruses can grow to such high titres in these cells. Therefore, 
there may be host barriers in place in E.Derm cells that are combating infection 
with influenza. If these host barriers exist, it could indicate that more 
meaningful results can be concluded from in vitro studies using these cells, as 
opposed to MDCK cells. In addition, considering these potential barriers is 
important when looking at transcriptomic data, as there may be a higher number 
of active genes due to a higher capacity to block infection. 
 
Unlike MDCK cells, which are highly susceptible to almost every influenza 
virus, E.Derm cells appear to be selective for which influenza viruses they can 
be infected by (Figure 9). This was shown by the low infectivity of CIV in E.Derm 
cells (C+D). There weren’t a high number of new virions produced during 
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infection, whereas CIV grew to similar titres as EIV in MDCK cells (A+B). The 
contrasting growth of CIV in E.Derm and MDCK cells, is an important finding as it 
corroborates what is seen in vivo, that is, that CIV cannot go back along its 
evolutionary path and infect horses (Yamanaka et al. 2012). Recent research in 
Pablo Murcia’s lab has demonstrated that this decrease in infectivity is due to 
the HA and NA proteins of the CIV virus. Work carried out by myself and Dr 
Gaelle Gonzalez showed that when we substituted the HA and NA of CIV with 
that of EIV, the infection phenotype is rescued. (My involvement in this work 
included: reverse genetics to produce different virus combinations, growth and 
titration of virus stocks, preparation of ex vivo tracheal explants, infection of 
tracheal explants, collection of data – infected explants and bead clearance, 
titration of virus from tracheal explants, immunohistochemistry staining of 
explants. Not involved in: taking images of immunohistochemistry). The reduced 
infectivity of CIV could be due to the sialic acid receptors distributed on the cell 
surface of E.Derm cells. MDCK cells have both SAα2, 3Gal and SAα2, 6Gal linked 
sialic acids (Ito et al. 1997). Collaborators at Cornell University are currently 
studying these receptors in E.Derm cells. Both EIV and CIV prefer SAα2, 3Gal 
linkages (Feng et al. 2015), although it has been shown that there may be 
additional glycan features at play that make sialic acid preferences more 
complex than previously believed (Gambaryan et al. 2005).  
 
When looking at the transcriptome of a cell, it is important that the cell is 
IFN competent. Cells such as Vero cells have lost their ability to produce IFN, 
therefore these cells are very useful when it comes to growing up certain virus 
stocks, but they don’t allow for the full picture of how a cell would try to 
combat a viral infection (Desmyter et al. 1968). To assess whether E.Derm cells 
were IFN competent, these cells were treated with Universal IFN (IFN-α) for 4 
and 24 hours (the time-points that would later be used for transcriptomic 
analysis). Following the IFN-α treatment, these cells were challenged with a 
VSV-ΔG-GFP replication-incompetent virus. This challenge experiment was 
repeated, but the cells were treated with Poly I:C, a mimic of double-stranded 
RNA, and challenged them with VSV-ΔG-GFP. Protection from infection could be 
seen at 4 hours post-treatment, and increasing at 24 hours. The protection 
effect increased with treatment concentration for both IFN-α and Poly I:C 
(Figure 10). Future experiments, in agreement with the literature, will use IFN-
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α at a concentration of 1,000 UI/ml, as there was very little difference by 
increasing the concentration to 10,000 UI/ml. 
 
Overall an in-depth characterisation of an equine cell line was described, 
which can be used for the extensive in vitro analysis of EIV and other related 
influenza viruses. It was demonstrated that this cell line provided a good means 
to study the transcriptome response, as the equine E.Derm cells were IFN 
competent, as opposed to MDCK cells. The remaining chapters will describe 
infection with different influenza viruses, and detailed transcriptomic analyses. 
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3.1. Introduction 
Some viruses are capable of crossing host species barriers to infect new animal 
and human hosts (Cheung & Poon 2007). A better understanding of what these 
barriers are, and how pathogens have evolved to overcome them, will enhance 
prediction and preparation for potential future outbreaks.  
 
Influenza A viruses (IAVs) of animals are all believed to have their 
ancestry in wild aquatic birds (Kawaoka et al. 1988). There are only a limited 
number of influenza subtypes that have become established in mammals, for 
example H1N1 in pigs (Shope 1931), H3N8 in horses (Oxburgh et al. 1994), and 
H3N2 and H1N1 in humans (Rambaut et al. 2008). The horse appears to play an 
important role in influenza emergence. It has been documented as a natural host 
for sustained influenza transmission on at least three occasions. There was an 
outbreak in 1872 of an unknown Equine Influenza Virus (EIV) subtype (Morens & 
Taubenberger 2010), an H7N7 EIV was first isolated in 1956 (Sovinova et al. 
1958), and an H3N8 EIV that was first identified in 1963 (Waddell et al. 1963).   
 
Many within-host barriers exist to stop entry and replication of influenza 
viruses (Kuiken et al. 2006). The virus must first find the correct tissues in which 
it can replicate. Finding the correct tissues may require overcoming physical 
barriers such as mucus and cilia in the respiratory tract (Zanin et al. 2015). Once 
it reaches the correct tissue, the virus must use the appropriate receptors to 
bind to and enter a cell. These receptors will vary depending upon the 
haemagglutinin (HA) of the influenza virus. For example, avian influenza viruses 
(AIVs) preferentially bind to Sialic Acid (SA) -α-2,3-Gal-terminated saccharides, 
as do equine and canine influenza viruses (EIV and CIV, respectively) (Pecoraro 
et al. 2013). In contrast, human influenza viruses bind to SA-α-2,6-Gal-
terminated saccharides (Couceiro et al. 1993). These distinctions in receptor 
binding result from different SA distributions within the host species. The 
trachea (the main site of influenza infection) in humans has a high distribution 
of SA-α-2,6-Gal-linkages, whereas equine tracheas are abundant with SA-α-2,3-
Gal linkages (Suzuki et al. 2000). Different receptor distributions may explain 
why AIV replication in humans is limited, whereas AIVs have jumped the host-
species barrier to infect horses on more than one occasion. 
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Once a virus enters a cell it must be able to replicate efficiently and 
continue to infect neighbouring cells. There are many factors that can affect the 
successful replication and dissemination of an IAV (Naffakh et al. 2000). 
Cleavage of HA by cellular proteases is an essential step of the replication cycle. 
Viruses that are not cleaved are not infectious, as cleaving of the glycoprotein 
enables the mature virus to bind to host cells. The HA of human influenza viruses 
and Low Pathogenic Avian Influenza (LPAI) are cleaved by trypsin-like proteases, 
thereby restricting virus tropism to where these proteases are present. For 
humans, these proteases are found in the respiratory tract, and for birds they 
are either found in the respiratory or intestinal tract, or both (Garten et al. 
1981; Klenk et al. 1975).  
 
An essential host barrier is the IFN response, which consists of a complex 
group of signalling proteins that are released in response to a pathogen, such as 
a virus, infecting a cell (Randall & Goodbourn 2008). These signalling proteins 
cause the cell to enter an antiviral state, and send signals to surrounding cells to 
heighten their viral defences. To overcome the IFN response, IAVs have adapted 
antagonists such as the non-structural (NS1) protein, which target the cellular 
response to infection (Hale, Randall, et al. 2008). However, the antagonistic 
protein can be host-specific and therefore it takes time for influenza viruses to 
adapt to new hosts. 
 
As horses possess similar SA receptors as birds, there is a continual 
possibility that a new avian influenza sub-type could emerge in horses. In 1989 in 
Jilin, a Chinese province, such an event occurred. A cross-species transmission of 
an H3N8 influenza virus caused severe mortality, with up to 20% of horses dying 
in some herds (Guo et al. 1992). H3N8 viruses are a commonly isolated subtype 
from avian reservoirs (Sharp et al. 1997) and have crossed the host species 
barriers on multiple occasions to infect mammals such as seals and camels 
(Anthony et al. 2012). Therefore, it is important to study the ability of H3N8 
AIVs to replicate in horses, and how they can overcome the host barriers 
described. 
 
The horse is not a dead-end host for influenza H3N8. Two viruses isolated 
from pigs with respiratory disease in 2005 and 2006 were shown to be most 
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closely related to EIVs (Tu et al. 2009). In addition, EIV jumped into dogs on 
multiple occasions (Crawford et al. 2005; Daly et al. 2008) and established as 
canine influenza virus (CIV) infection in dogs in North America. Therefore, it is 
important to study influenza in the context of the horse in order understand how 
an IAV can switch hosts. 
 
This chapter describes an analysis that aimed to investigate the host 
barriers to the emergence of an avian virus into an equine host, and the 
adaptation of the virus to the host. A panel of four distinct IAVs were selected: 
(a) an H3N8 AIV (AIV/2009) isolated during surveillance studies in Mongolia from 
wild birds (Gilbert et al. 2012), (b) an EIV first isolated in 1963 (EIV/1963) [the 
virus isolate was used for tracheal explant infections, the reverse genetics virus 
was used for in vitro experiments], (c) a reverse genetics virus of an EIV isolated 
after 40 years of adaptation to the horse (EIV/2003), and (d) a reverse genetics 
virus of a CIV isolate (CIV/2009). CIV is interesting to study, as it will provide a 
virus in the context of a virus departing from a host species and continuing to 
evolve.  
 
In this chapter, both ex vivo equine tracheal explants, and in vitro equine 
dermal cells (E.Derm) were used for infections in order to investigate how 
evolutionary distinct viruses replicate in an equine host. The growth kinetics of 
each virus were compared using both systems and observing the infection 
characteristics. In order to assess correct protease availability as a restriction 
for influenza, the growth kinetics of the viruses were compared in cells treated 
with and without an exogenous trypsin protease. Finally, to characterize the 
ability of each of the selected viruses to overcome the equine IFN response, cells 
were induced into an antiviral state and then infected (Ronni et al. 1997).  
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3.2. Results 
3.2.1.  Ex vivo horse trachea explants are interferon competent 
To establish whether ex vivo horse trachea explants would be a suitable future 
system to study influenza infections, it was first necessary to determine whether 
they could produce an IFN response. Horse tracheal explants were treated with 
increasing concentrations of IFN-α consisting of 10, 100, and 1000 units for 24 
hours (Figure 11). The upregulation of the IFN response was investigated by 
targeting the well-known Interferon Stimulated Gene (ISG) Mx1 (Myxovirus 
Resistance Protein 1), using immunohistochemistry staining. Mx1 is constitutively 
expressed in the respiratory tract (Chang et al. 1990), and, consequently, a 
background level of Mx1 expression was present in the upper epithelial cells of 
the control tissue. The staining, and therefore the expression of Mx1, increased 
sharply with increasing concentration of IFN treatment – spreading to all the 
epithelial cells throughout the tissue. Treatment of 1000 units of IFN saw many 
additional cells in the lamina propria1 expressing Mx1. 
 
 
Figure 11: Immunohistochemistry staining of Mx1 in horse trachea explants treated with 
increasing concentrations of IFN-α for 24 hours. (Antibody: Mab143 anti-Mx1) 
 
3.2.2. Influenza viruses have different infection phenotypes in ex vivo horse 
tracheal explants 
Ex vivo horse tracheal explants were infected with the selected panel of 
influenza viruses. Figure 12 (A) demonstrates that EIV/2003 grew to much 
higher titres than the other influenza A viruses (IAVs). The highest EIV/2003 titre 
was found at 5 days post-infection (~3.51x109 PFU/ml), with significant 
differences when compared to Mock-infected explants at 3 and 5 days post-
                                         
1 A thin layer of loose connective tissue that lies beneath the epithelium. 
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infection (*). Infection with EIV/1963 resulted in lower titres, with a peak at 3 
days post-infection of ~7.86x105 PFU/ml, four logs lower than EIV/2003 at the 
same time-point. Statistical analysis revealed there was a significant difference 
(*) between EIV/1863 and Mock-infected explants at 4 days post-infection. 
CIV/2009 also had very low replication kinetics, with a peak of infection at 2 
days post-infection of 8.67x104 PFU/ml, four logs lower than EIV/2003 at the 
same time-point. The growth kinetics of AIV/2009 was very sporadic, with 
positive virus titres found only at 2 and 4 days post-infection, and no virus 
growth detected in between. However, day 4 post-infection was shown to be 
significantly different (*) than Mock-infected. 
 
 
Figure 12: Equine tracheal explants were infected with AIV/2009, EIV/1963, EIV/2003 and 
CIV/2009 at 200 PFU (based on MDCK titre). (A) The virus growth kinetics. (B) Bead clearance 
assay, bars represent the average time for bead clearance. Experiments with AIV/2009 were 
repeated independently two times, experiments were the other viruses were repeated 
independently three times; error bars indicate the mean with range of the values. For each 
figure a statistical t-test was carried out, comparing the values to no treatment. Significance is 
shown with * where p≤0.05. 
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A coloured bead clearance assay was used to determine the ciliary function of 
the infected explants, and to ensure the healthiness of the Mock-infected 
controls (Figure 12, B). Explants infected with both EIVs showed impairment in 
bead clearance beginning at day 2 post-infection. For EIV/2003 the impairment 
was significantly different (*) at day 4 and 5 post-infection, as compared to the 
Mock-infected explants. The explants infected with EIV/1963 appeared to 
deteriorate faster, with a significant difference (*) shown earlier at 3 days post-
infection, and again at 5 days post-infection with bead clearance time increasing 
to ~25 minutes. Infection with CIV/2009 leads to decrease in bead clearance 
time at day 3 post-infection onwards. Day 5 post-infection was the only time 
that showed a significant difference (*) when compared to the bead clearance of 
Mock-infected explants. The bead assay carried out on AIV/2009 infected 
explants did not show any decreased ciliary function, and so these virus 
infections were not significantly different from the Mock-infected explants.  
 
3.2.3.  In vitro infection with influenza viruses is similar to infections of ex 
vivo tracheal explants 
To analyse potential host barriers to influenza infection, it was necessary to 
perform infections in vitro using an equine cell line. An equine dermal cell line 
(E.Derm) cell line was selected due to being permissive for infection with EIV. 
The infections using E.Derm cells were compared to infections in MDCK cells, 
which are considered permissive to most influenza viruses and therefore act as a 
control. 
 
Infection with the panel of influenza viruses in MDCK cells demonstrated that 
EIV/1963, EIV/2003 and CIV/2009 grew to similar titres. AIV/2009 was lower, 
with a difference of around 3-4 logs at 72 hours post-infection (Figure 13, A). 
The only virus that showed a significant difference in viral titre when compared 
to Mock-infected cells was EIV/1963 at 72 hours post-infection (*). When looking 
at intracellular virus, AIV/2009 seemed to infect faster, with a significant 
difference (*) at 24 hours post-infection as opposed to the other viruses, which 
were not significantly different (Figure 13, B). This difference is also significant 
at 48 and 72 hours post-infection. The avian virus also had the highest 
percentage of infected cells at 72 hours post-infection (~90.4%). This is in 
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contradiction to the extracellular virus titrated using plaque assays, where 
AIV/2009 had the lowest titre of 8.2x105 PFU/ml at 72 hours post infection (3-4 
logs lower than the other influenza viruses). The high percentage of infected 
cells could be explained due to the fact that AIV/2009 appears to kill a large 
proportion of cells, leaving fewer alive cells that are infected. This complicates 
any discussion of the proportion of intracellular virus, and must be kept in mind 
when observing the high percentage of infected cells with AIV/2009. 
 
CIV/2009 infected MDCK cells quickly, with ~31.7% of positive cells at 24 hours 
post-infected. The CIV/2009 virus titre was the highest of the viruses (2.8x105 
PFU/ml) at this time-point. However, the growth slowed in comparison to both 
EIVs, which were about 0.4 logs higher at 72 hours post-infection. It was shown 
to be significantly different (*) at 48 and 72 hours post-infection when compared 
to Mock-infected cells. Both EIV/1963 and EIV/2003 also showed a significant 
difference (*) when compared to Mock-infected cells at 48 and 72 hours post-
infection.  
 
When the same panel of influenza viruses were used to infect E.Derm cells, 
EIV/2003 was significantly different in virus titre when compared to Mock-
infected cells, reaching titres of 4.7x109 PFU/ml and 2.5x109 PFU/ml at 24 and 
48 hours post-infection (*). All of the viruses had the same pattern of growth 
kinetics, peaking at 24 hours post-infection with significant difference (*), and 
decreasing at later time-points (Figure 13, C). Only CIV/2009 was also 
significantly different (*) at 48 hours post-infection when compared to Mock-
infection, with a virus titre of 4.1x103 PFU/ml. 
 
In regards to intracellular virus, AIV/2009, EIV/1963 and EIV/2003 had similar 
proportions of infected cells, with CIV/2009 infecting fewer cells. Similarly to 
infection in MDCK cells, AIV/2009 infected a high proportion of cells, but 
produced a relatively low viral titre. The avian virus had the highest number of 
cells infected compared to the other viruses at 72 hours post-infection (~69.1% 
as opposed to the next highest ~63.1%, of EIV/2003) (Figure 13, D). All four 
viruses were significantly different (*) at 24, 48 and 72 hours post-infection when 
compared to Mock-infected cells. 
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MDCK and E.Derm cells were observed using a light microscope to assess 
cytopathic effects (CPE) of infection (Figure 14, Figure 15, and Figure 16). For 
both cell lines, the infection that caused the greatest CPE was when cells were 
infected with AIV/2009. The rounding of cells began much sooner and with a 
greater number than was found with the other viruses. By 72 hours post-
infection, there were very few cells left attached to the plate. The other three 
viruses produced similar CPE in MDCK cells, with rounding of cells and 
detachment from the monolayer. In E.Derm cells, EIV/1963 induced a lot of CPE 
in comparison to EIV/2003 and CIV/2009. By 72 hours post-infection there were 
very few cells left of the monolayer and there were a lot of round cells. For 
EIV/2003 and CIV/2009, there wasn’t very much CPE observed. There were 
slightly more rounded cells for infection with EIV/2003 when compared to 
CIV/2009. 
 
 
Figure 13: Growth curves of infections with AIV/2009, EIV/1963, EIV/2003 and CIV/2009, MOI 0.1 
(based on MDCK titre). Intracellular and extracellular virus is shown for MDCK (A+B) and E.Derm 
cells (C+D). Infected cells were measured using the Guava Flow Cytometer. Experiments were 
repeated independently three times; error bars indicate the mean with range of the values. For 
each figure a statistical t-test was carried out, comparing the values of Mock-infected cells to 
each of the virus-infected cells. Significance is shown with * where p≤0.05. 
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Figure 14: Light microscopy images of MDCK and E.Derm cells infected with AIV/2009, EIV/1963, 
EIV/2003 and CIV/2009 at 24 hours post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars 
represent 1,000µm. (Magnification x4) 
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Figure 15: Light microscopy images of MDCK and E.Derm cells infected with AIV/2009, EIV/1963, 
EIV/2003 and CIV/2009 at 48 hours post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars 
represent 1,000µm. (Magnification x4) 
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Figure 16: Light microscopy images of MDCK and E.Derm cells infected with AIV/2009, EIV/1963, 
EIV/2003 and CIV/2009 at 72 hours post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars 
represent 1,000µm. (Magnification x4) 
Chapter 3: Barriers to infection 
 
72 
3.2.4. The addition of TPCK trypsin during replication increases the 
infection efficiency of less adapted influenza viruses 
The addition of exogenous proteases is a requirement for most IAVs to replicate 
successfully in MDCK cells. To investigate whether the presence of exogenous 
proteases would increase infection kinetics of the viruses, the panel of IAVs were 
grown in E.Derm cells with and without the addition of an exogenous protease in 
the form of TPCK trypsin (Figure 17, A). 
 
 
Figure 17: (A) Growth curves of intracellular virus in E.Derm cells infected with AIV/20009, 
EIV/1963, EIV/2003 and CIV/2009 with MOI 0.1 (based on MDCK titre), with and without the 
addition of exogenous TPCK trypsin in the infection media. (B) Ratio of percentage of infected 
cells without the addition of TPCK trypsin, divided by percentage of infected cells with the 
addition of TPCK trypsin. Infected cells were measured using the Guava Flow Cytometer. 
Experiments were repeated independently three times; error bars indicate the mean with range 
of the values. For each figure a statistical t-test was carried out, (A) comparing the values in the 
presence and absence of TPCK trypsin, (B) comparing the values to EIV/2003. Significance is 
shown with * where p≤0.05. 
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The virus that appeared to benefit the most from the addition of TPCK trypsin 
was AIV/20009, with significant differences (*) between virus grown in the 
presence of TPCK trypsin and virus grown in regular growth media at all time-
points. The ratio (Figure 17, B) was calculated for the percentage of untreated 
infected cells divided by the percentage of TPCK trypsin treated infected cells. 
The closer the ratio is to 1, the less affected the virus is by the addition of an 
exogenous protease. For AIV/2009, this was ~0.69, ~0.76 and ~0.70 at 24, 48 and 
72 hours post-infection, respectively. The ratio was shown to be significantly 
different (*) between AIV/2009 and EIV/2003 at 48 hours post-infection. 
 
CIV/2009 was affected positively by the addition of TPCK trypsin. The 
percentage of cells infected showed significant differences at 48 hours and 72 
hours post-infection (*), between the percentage of cells infected with and 
without the addition of TPCK trypsin to the infection media. CIV/2009 also had 
the lowest ratio when the percentage of cells infected in a regular infection, 
were divided by the percentage of cells infected in the presence of TPCK 
trypsin. At 24, 48 and 72 hours post-infection, this ratio was ~0.54, ~0.52 and 
~0.30, respectively. There was a significant difference (*) when this ratio was 
compared to the ratio of EIV/2003, at 48 and 72 hours post- infection. 
 
EIV/1963 showed a significant difference (*) in percentage of cells infected with 
and without the addition of TPCK trypsin at 24 hours post-infection - the 
percentage of cells infected in the presence of TPCK trypsin was less. For 
EIV/1963 this was ~1.65 at 24 hours post-infection, very high above the ratio of 
1. In fact, as it was higher than 1, this means that EIV/1963 actually seemed to 
replicate more efficiently without the addition of TPCK. For 48 and 72 hours this 
decreased to ~0.98 and ~0.97, respectively. When compared to the ratio of 
EIV/2003, the only time-point where EIV/1963 was significantly different was at 
24 hours post-infection (*). 
 
The infection of EIV/2003 with and without TPCK trypsin also does not seem to 
be highly affected, similar to EIV/1963. The ratio of infection is ~0.82, ~1.14 and 
~0.88 at 24, 48 and 72 hours post-infection. The higher ratio at 48 hours post-
infection means the percentage of cells infected without the presence of TPCK 
trypsin was actually higher than with the addition of TPCK trypsin. 
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Light microscopy images were taken of the infections at each day post-infection 
(Figure 18, Figure 19, and Figure 20). It is important to note that it has been 
previously determined that TPCK trypsin is harmful to E.Derm cells. Therefore 
the images taken in the presence of TPCK trypsin naturally had a lot more CPE 
due to this effect. However, there did appear to be a marked increase in cell 
death between cells treated with and without TPCK trypsin in the case of 
infection with AIV/2009 and CIV/2009. The marked increased for AIV/2009 and 
CIV/2009 agreed with the findings that these were also the viruses that 
benefited the most from the addition of TPCK trypsin during infection. 
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Figure 18: Light microscopy images of E.Derm cells infected in the presence or absence of TPCK 
trypsin. A panel of viruses were tested: AIV/2009, EIV/1963, EIV/2003 and CIV/2009 at 24 hours 
post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars represent 1,000µm. (Magnification 
x4) 
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Figure 19: Light microscopy images of E.Derm cells infected in the presence or absence of TPCK 
trypsin. A panel of viruses were tested: AIV/2009, EIV/1963, EIV/2003 and CIV/2009 at 48 hours 
post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars represent 1,000µm. (Magnification 
x4) 
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Figure 20: Light microscopy images of E.Derm cells infected in the presence or absence of TPCK 
trypsin. A panel of viruses were tested: AIV/2009, EIV/1963, EIV/2003 and CIV/2009 at 72 hours 
post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars represent 1,000µm. (Magnification 
x4) 
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3.2.5. Less evolutionary adapted influenza viruses were highly affected by 
IFN-α pre-treatment before infection 
In order to assess the capacity of the selected IAVs to antagonize an antiviral 
response, viruses were used to infect E.Derm cells that had been pre-treated 
with 1,000 UI/ml of IFN-α for 24 hours. The antiviral state of the cells was 
confirmed by infection with a VSV-ΔG-GFP virus (data not shown). Vesicular 
stomatitis virus (VSV) is a virus that is highly sensitive to IFN and can therefore 
be used as a control to assess the presence of an IFN response in cells. This 
particular virus is missing the gene that encodes glycoprotein and is therefore 
replication incompetent. As VSV is a virus tagged with green fluorescent protein 
(GFP), infected cells can be easily identified to quantify infection. All of these 
elements mean that VSV-ΔG-GFP is a very useful virus for testing the antiviral 
state of cells. 
 
All of the IAV viruses infected fewer cells when grown in E.Derm cells in an 
antiviral state (Figure 21, A), as measured using the Guava Flow Cytometer. 
Infection with AIV/2009 showed a significant difference (*) in the percentage of 
pre-treated and untreated infected cells at all of the time-points checked (24h: 
~32.6% and ~57.3%, 48h: ~27.6% and ~69.5%, 72h: ~36.8% and ~69% for IFN-α pre-
treated and untreated cells respectively). The same pattern was observed for 
EIV/1963, a significant difference (*) in the percentage of infected cells between 
IFN-α pre-treated and untreated cells was observed (24h: ~15.2% and ~37.7%, 
48h: ~5.3% and ~32.3%, 72h: ~7.2% and ~57.8% for IFN-α pre-treated and 
untreated cells respectively). CIV/2009 only showed a significant difference (*) 
between pre-treated and untreated infected cells at 48 hours post-infection 
(~12.2% and ~23.7% for IFN-α pre-treated and untreated cells respectively). 
There was no significant difference for EIV/2003 when grown in cells with or 
without the pre-treatment of IFN-α.  
 
The ratio of infection with IFN-α pre-treatment divided by no IFN-α treatment 
(+IFN-α/- IFN-α) was compared between viruses (Figure 21, B). The closer the 
ratio was to 1, the less affected the virus was by IFN-α pre-treatment. EIV/2003 
was the virus that was least affected by IFN-α pre-treatment as it had the 
highest ratio of 0.85 at 48 hours post-infection. The virus that was most affected 
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by IFN-α pre-treatment was EIV/1963, which had the lowest ratio of 0.12 found 
at 72 hours post-infection. The ratio for AIV/2009, EIV/1963, and CIV/2009 were 
all shown to be statistically different (*) to the EIV/2003 ratio at all three time-
points.  
 
The phenotype of infection was affected by pre-treatment of the E.Derm cells 
with IFN-α, as can be seen in Figure 22, Figure 23, and Figure 24. For all of the 
infections with IAV, there was less cell rounding and detachment in the 
infections after pre-treatment with IFN-α. Less rounding and detachment was 
most apparent for AIV/2009 and EIV/1963. For the infection with AIV/2009, very 
few attached cells remained at 72 hours post-infection. Whereas when the cells 
were pre-treated with IFN-α and infected with AIV/2009 the monolayer 
remained, although there were still a lot of dead cells present. At 72 hours post-
infection with EIV/1963 there were still cells attached but there was a lot of cell 
death, which was much decreased in the infection after pre-treatment with IFN-
α. 
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Figure 21: (A) Growth curves of intracellular virus in E.Derm cells infected with AIV/2009, 
EIV/1963, EIV/2003 and CIV/2009, MOI 0.1 (based on MDCK titre), with and without 24 hours of 
pre-treatment with 1,000 UI/ml of IFN-α. (B) Ratio of percentage of infected cells with IFN-α 
pre-treatment, divided by percentage of infected cells without IFN-α pre-treatment. Infected 
cells were measured using the Guava Flow Cytometer. Experiments were repeated independently 
three times; error bars indicate the mean with range of the values. For each figure a statistical 
t-test was carried out, (A) comparing the values in the presence and absence of TPCK trypsin, (B) 
comparing the values to EIV/2003. Significance is shown with * where p≤0.05. 
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Figure 22: Light microscopy images of E.Derm cells infected with or without 24 hours of pre-
treatment with 1,000 UI/ml of IFN-α. A panel of viruses were tested, AIV/2009, EIV/1963, 
EIV/2003 and CIV/2009 at 24 hours post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars 
represent 1,000µm. (Magnification x4) 
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Figure 23: Light microscopy images of E.Derm cells infected with or without 24 hours of pre-
treatment with 1,000 UI/ml of IFN-α. A panel of viruses were tested, AIV/2009, EIV/1963, 
EIV/2003 and CIV/2009 at 48 hours post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars 
represent 1,000µm. (Magnification x4) 
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Figure 24: Light microscopy images of E.Derm cells infected with or without 24 hours of pre-
treatment with 1,000 UI/ml of IFN-α. A panel of viruses were tested, AIV/2009, EIV/1963, 
EIV/2003 and CIV/2009 at 72 hours post-infection, MOI 0.1 (based on MDCK titre). Horizontal bars 
represent 1,000µm. (Magnification x4) 
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3.3. Discussion 
Host barriers to infection with influenza A viruses (IAVs) have not been fully 
characterized for any hosts, including the horse. It is necessary to understand 
equine barriers to influenza infection, in order to better prevent cross-species 
transmission of IAVs to horses. Understanding equine barriers is also important as 
horses can be used as a model to better identify how IAVs infect humans. 
 
A previously established ex vivo tracheal organ culture system (Nunes et 
al. 2010) was used to culture tracheal explants from horses. In this chapter, it 
was shown that these explants retain the ability to mount an interferon (IFN) 
response by treating the explants for 24 hours with IFN-α. Mx1 (Myxovirus 
Resistance Protein 1) was increasingly detected in the epithelial cells, extending 
to the cells in the lamina propria with higher concentrations of treatment 
(Figure 11). The presence of Mx1 means that studies with influenza infection 
using the ex vivo model are relevant, as they involve the IFN response.  
 
Of note, the horse trachea used for the IFN treatment experiment was 
from a vaccinated horse and therefore would be resistant to ex vivo infection 
with EIV. Mx1 expression is quite high in the Mock-treated tracheal explants 
(Figure 11), which can be explained as it has been shown to be constitutively 
expressed in the respiratory tract (Chang et al. 1990).  
 
Infection with the repertoire of viruses (EIV/1963, EIV/2003, AIV/2009, 
and CIV/2009) in the equine tracheal explants demonstrated differing growth 
kinetics (Figure 12). The virus that replicated most efficiently was EIV/2003, 
which was as expected, as EIV/2003 is the virus that is most adapted to an 
equine host. AIV/2009 replicated very sporadically, with no virus titre detected 
on several days of infection. CIV/2009 grew to low titres, which mimics what is 
reported in nature – CIV cannot infect horses (Yamanaka et al. 2012). EIV/1963 
grew to lower titres than EIV/2003, but produced a faster decrease in ciliary 
function, as measured by a coloured bead assay. EIV/2003 also induced a 
blockage to bead clearance from the explant, meaning that infection was 
damaging the cilia. AIV/2009 did not cause any reduction in ciliary function, and 
CIV/2009 only a little at later days of infection. These results suggest that both 
the AIV/2009 and CIV/2009 viruses did not damage the epithelial cells of the 
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explants. Overall, the most adapted viruses to equine tracheal explants are the 
two EIV viruses, with limited replication by CIV/2009. AIV/2009 did not seem to 
easily replicate in the tracheal explants, suggesting that it is not adapted for 
replication in an equine host.  
 
The aim of studying in vitro infections of E.Derm cells was to have a 
convenient model to better understand the barriers a virus has to overcome to 
adapt to its new host. MDCK and E.Derm cells were infected with a panel of four 
viruses. Virus replication in MDCK cells was very similar between the viruses, 
except for AIV/2009, which replicated 3-4 logs lower at 72 hours post-infection 
(Figure 13, A+B). Some avian influenza viruses (AIVs) replicate better in eggs 
rather than in cells, as is the case for this avian virus (Parvin et al. 2015). As for 
virus growth kinetics in E.Derm cells, there was a large distinction between the 
viruses (Figure 13, C+D). CIV/2009 replicated at very low titres, similar to the 
growth kinetics in the tracheal explants. EIV/1963 was much lower when 
compared to the titre of EIV/2003, which grew as high as 109 PFU/ml. The virus 
titre and percentage of cells infected of AIV/2009 were contrasting. The virus 
did not grow to very high titres, yet at 72 hours it had infected the highest 
percentage of cells out of the panel of viruses tested. An explanation for this 
may be that the virus could be producing Defective Interfering Particles (DIPs) 
that would not be detected in a plaque assay, which only detects infectious 
particles (Frensing et al. 2014). AIV/2009 also produced much higher cell death 
in both MDCKs and E.Derm cells. The virus could possibly be infecting the cells, 
but producing an abortive infection. Another reason could be that the avian virus 
does not titrate well on MDCK cells. If this experiment were to be repeated, it 
would be useful to measure virus production using another method to measure 
the viral genome load.  
 
It has been extensively shown that proteases are essential for the 
replication of IAVs (Garten et al. 1981; Klenk et al. 1975). For a successful 
second round of replication, exiting virions must have the haemagglutinin (HA) 
proteins cleaved by proteases. This allows the maturation of the HA enabling it 
to bind to another new cell. Proteases are naturally present in certain cells, and 
are one of the factors that lead to tissue tropism by the virus (Steinhauer 1999). 
Infection of MDCKs requires the addition of an exogenous protease in the form of 
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TPCK trypsin (Tobita et al. 1975). As has previously been shown in this thesis, 
the correct proteases were present in E.Derm cells for the replication of 
EIV/2003 without the addition of TPCK trypsin. To test whether the replication 
of other IAVs would be affected by the addition of TPCK trypsin, and 
demonstrate that host proteases could be a barrier to infection, the viruses were 
grown with and without the presence of TPCK trypsin in the infection media. As 
seen in Figure 17, the viruses most affected by the addition of TPCK trypsin 
were AIV/2009 and CIV/2009. The reason for this could be that both viruses are 
not adapted to an equine host, and therefore are not evolutionarily modified to 
use equine proteases to cleave the HA protein. In support of this, the equine 
viruses (EIV/1963 and EIV/2003) were not positively affected by the addition of 
exogenous proteases. The lack of a positive affect for the EIVs means that they 
were already replicating efficiently using equine proteases, to which they were 
well adapted. Figure 18, Figure 19, and Figure 20 show the light microscopy 
images of infection with and without TPCK trypsin. It is important to remember 
that E.Derm cells were negatively affected by the presence of TPCK trypsin, 
causing rounding of cells and detachment, as can be seen in Mock cells at 48 and 
72 hours post-infection. However, taking this into account, infection with 
AIV/2009 and CIV/2009 in the presence of TPCK trypsin induced a marked 
increase of cell death and monolayer destruction. 
 
One of the greatest barriers to viral infection is the IFN response. In order 
to study this effect on the panel of viruses, E.Derm cells were pre-treated for 24 
hours with IFN-α to establish an antiviral state before being infected (Figure 
21). All of the viruses were affected negatively, as shown by the ratio of the 
percentage of regularly infected cells, divided by the percentage of infected 
cells after pre-treatment with IFN-α. Each virus had a ratio less than one, which 
means that the viruses infected less cells with IFN-α pre-treatment than 
without.  
 
As H3N8 AIVs have crossed the host-species barrier to infect the horse on 
more than one occasion (Morens & Taubenberger 2010; Sovinova et al. 1958; 
Waddell et al. 1963), it was important to study the replication of an H3N8 of 
avian-origin in equine tracheal explants (Figure 11, A) and E.Derm cells (Figure 
13, C). The AIV/2009 virus replicated to higher consistent titres in E.Derm cells 
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than in tracheal explants, suggesting that a host barrier was present in the ex 
vivo tissue that is not found in vitro. When comparing replication with and 
without the presence of exogenous proteases in the form of TPCK trypsin, 
AIV/2009 infect a significantly higher percentage of cells when grown in the 
presence of TPCK trypsin (Figure 17). High replication rates in the presence of 
TPCK trypsin suggests that AIV/2009 could benefit from the presence of an 
exogenous trypsin, and that equine proteases may not sufficiently cleave the HA 
of the avian virus. In addition, there was a significant difference when AIV/2009 
was grown in cells pre-treated with IFN-α. The AIV/2009 was therefore greatly 
restricted by an equine IFN response, which would be a significant barrier to 
infection if this virus ever spilled over into a horse. 
 
The equine virus EIV/1963 is an influenza virus of avian-origin, which may 
not have had sufficient time to fully adapt to an equine host. In comparison to 
EIV/2003, the EIV/1963 virus replicated to considerably lower titres in both the 
tracheal explants and E.Derm cells (Figure 12, A and Figure 13, C). The 
addition of TPCK trypsin to the infection media did not cause a positive increase 
in viral replication (Figure 17). In fact, EIV/1963 infected a higher percentage of 
cells when not grown in the presence of TPCK trypsin, a phenomenon which was 
also observed by Capua et al. (Capua et al. 2013). Treatment with IFN-α 
significantly inhibited virus growth, meaning that EIV/1963 has not had the time 
to adapt to counteract the mammalian IFN response (Figure 13). 
 
EIV/2003 has had 40 years to adapt to its equine host, and it replicated to 
the highest titre in equine tracheal explants (Figure 12, A) and E.Derm cells 
(Figure 13, C). Interestingly, EIV/2003 was affected least by the pre-treatment 
of the cells with IFN-α (Figure 13). The lack of a pre-treatment effect suggests 
that EIV/2003 has evolved ways to counter-act the anti-viral response and can 
replicate to high titres even in the presence of IFN. The main antagonist of the 
IFN response in IAVs is the non-structural protein (NS1) (Hale, Randall, et al. 
2008). The NS1 of EIVs from the H3N8 lineage has evolved over time, and 
contributed to the adaptation of EIV to the horse (Chauché et al. 2017). The 
addition of TPCK trypsin to the media did not boost the replication kinetics of 
EIV/2003 (Figure 17), revealing that EIV/2003 was already replicating efficiently 
using equine proteases present in E.Derm cells. 
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In the case of CIV, it is not known why the virus cannot infect horses after 
it evolved from an EIV (Figure 13, A). The results in this chapter may shed some 
light onto why this may be. The infection of E.Derm cells with CIV after pre-
treatment with IFN-α shows that they are indeed affected, but not as 
significantly as EIV/1963 (Figure 13). The presence of infected cells is 
interesting, as CIV/2009 may be more evolved than EIV/1963 to counteract the 
mammalian anti-viral response, and so be able to replicate at the same relative 
efficiency after IFN-α pre-treatment. As for the experiment studying the effect 
of addition of an exogenous protease, this boosted the replication of CIV 
significantly (Figure 17). The boosting effect of adding exogenous protease 
suggests that the equine proteases are not compatible for the successful 
replication of CIV. When these were replaced exogenously with TPCK tryspin, 
the infection was rescued. These results implicate the HA and NA of CIV as 
determinants of viral restriction, and may give us an indication that the host 
proteases of horses are the barrier for CIV infection. 
 
This chapter has only looked at the affect of pre-treatment with IFN-α to 
infection with IAVs. It would be very interesting to look at pre-treatment with 
IFN-β and IFN-γ to see if similar results are observed, or if IFN-α is the only 
antagonist to virus replication in equine cells. Future studies could also use 
reverse genetics to investigate the non-structural protein (NS1) of these IAVs, in 
order to find out more about the evolution of this IFN antagonist protein and 
how it affects viral replication. 
 
There are many host barriers present to prevent host species 
transmission, and this chapter has only looked in more detail at two of these in 
the context of equine cells. Future research could compare these experiments in 
a canine cell line such as A72 cells (Feng et al. 2015), to determine whether CIV 
would be the most efficient virus that is least affected by IFN-α pre-treatment 
and the addition of TPCK trypsin. If such experiments showed these effects they 
would provide a greater strength to the argument that a virus will perform 
better within the context of its own host cell line and demonstrate that it has 
evolved to overcome the species barriers. 
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Overall, this chapter has looked in detail at two of the equine host 
barriers to influenza infection and demonstrated their effect on the replication 
of four different IAVs. EIV/2003, potentially the most highly adapted equine 
influenza from the panel of viruses, showed the greatest level of resilience to 
pre-treatment with IFN-α, and does not seem to be limited in replication by 
cellular proteases. The potentially un-adapted EIV/1963 was highly affected by 
the IFN response, but cellular proteases do not seem to be a limiting factor for 
its replication. The next chapter will use transcriptomics to study the gene 
expression of E.Derm cells upon infection with the two equine viruses. 
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4.1. Introduction 
Influenza A viruses (IAVs) are a significant pathogen of many birds and mammals 
causing high numbers of mortality. Originating in waterfowl (Kawaoka et al. 
1988), they have crossed species barriers to infect many other animals such as 
seals, humans and horses (Geraci et al. 1982; Rambaut et al. 2008; Oxburgh et 
al. 1994). These cross-species jumps do not occur readily due to within-host 
barriers against infection with foreign pathogens (Kuiken et al. 2006).   
 
The horse is a mammal that has been infected with influenza since at least 
1956, when it was first documented (Sovinova et al. 1958). An equine influenza 
virus (EIV) of the subtype H7N7 (H for Haemagglutinin and N for Neurominidase) 
was shown to infect horses, however this particular EIV is now considered to be 
extinct. It is thought that the old H7N7 was outcompeted by the new subtype to 
infect horses. In 1963, horses were first recorded as being infected with a new 
EIV of avian origin – the H3N8 subtype that led to the extinction of the old H7N7 
EIV (Waddell et al. 1963). The virus continued to circulate within horse 
populations and is still present to this day.    
 
After a spillover infection2, such as occurred with EIV in horses in 1963, 
the virus must establish onward transmission and infect new susceptible hosts if 
it is to be maintained within the new species. Therefore, it must quickly adapt 
and evolve to the novel barriers encountered in a new host. These barriers 
include sialic acid receptors, innate immunity and protease availability (Kuiken 
et al. 2006). 
 
IAVs are viruses that are able to evolve quickly in order to avoid the 
adaptive and innate immune responses of the hosts they infect (Steinhauer & 
Holland 1987). As RNA viruses, they have specific enzymes that drive the viral 
replication cycle – the RNA-dependent RNA polymerase (RdRp) (Lauring et al. 
2013; Robert G Webster et al. 1992). The RdRp is known to be error-prone, 
producing a very high mutation rate when replicating the viral genome (Penhoet 
et al. 1971). The random production of beneficial mutations helps the viruses to 
                                         
2 A spillover infection is a single event when a pathogen from one species infects 
another species, and has the potential to result in an outbreak. 
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escape the immune response or lead to new viral properties. However, evolving 
the ability for continuous transmission once in a new host species is a significant 
challenge due to the high number of mutations that can sometimes be required. 
 
The interferon (IFN) response is one of the greatest of the host barriers, 
turned on when an invading pathogen is detected and inducing neighbouring 
uninfected cells into an antiviral state (Guidotti & Chisari 2000). An antiviral 
state is produced by the presence of a cascade of IFN stimulated genes (ISGs) 
that can defend the cell from viral infection in many different ways (Randall & 
Goodbourn 2008; Goodbourn et al. 2000; Sadler & Williams 2008). For example, 
one of the most well known influenza ISGs is Mx1 (Myxovirus Resistance Protein 
1), a protein that has been shown to inhibit primary transcription, viral mRNA 
(messenger Ribo Nucleic Acid) translation, and the activity of the viral 
polymerase (Samuel 1991; Staeheli et al. 1986; Verhelst et al. 2012). There are 
different kinds of IFN, such as IFN-β and IFN-γ, but for the purposes of this study 
we will concentrate on the effects of treatment with IFN-α, which is a type I 
IFN. 
 
The non-structural protein (NS1) of IAVs in the main antagonist for the IFN 
response in cells, acting in different ways depending upon the specific virus 
(Hale, Randall, et al. 2008; Krug et al. 2003). The NS1 of EIV H3N8 has adapted 
over time through evolution in a mammalian host. The current research aims to 
study how a virus would control the host IFN response at different time points 
during its evolutionary history. 
 
A relatively recent tool developed to study the within-host dynamics of 
infection is the use of high-throughput RNA sequencing (RNA-seq) to examine 
cellular transcriptomes (Weber 2015). RNA-seq functions by sequencing the 
cellular RNAs and aligning them to a host genome in order to quantify which 
genes are being expressed. By comparing the results from an infected group of 
cells/tissue to control cells/tissue, it is possible to observe which genes are 
upregulated or downregulated – these are named Differentially Expressed (DE) 
genes. Different algorithms exist to produce these lists of DE genes such as 
edgeR and DeqSeq, but for the purpose of this chapter we have used the 
algorithm called CuffDiff2 (Trapnell et al. 2013).  
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 CuffDiff2 works by mapping the RNA-seq reads to a reference genome, 
and then calculates the transcript abundance to produce an output defined as: 
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) (Trapnell 
et al. 2013). The FPKM value for the combined replicates of each condition is 
compared to the FPKM value of the Mock-infected cells. This comparison allows 
the calculation of the fold change in the gene expression, which is reported as 
the Log2FoldChange (Log2FC). Competing methods such as DeSeq and edgeR may 
sometimes offer a higher gene-level sensitivity as they use count-based 
methods, but can produce a higher background of false positives (Seyednasrollah 
et al. 2013). As CuffDiff2 controls for cross-replicate variability and read-
mapping ambiguity, there should be less false positives identified. 
 
The aim of this chapter was to analyse the equine cellular response to 
treatment with IFN-α, and infection with two different H3N8 EIVs of evolutionary 
distinct origin. The cells used for the transcriptomic analysis were equine dermal 
(E.Derm) cells, infected with one EIV from when the virus had first infected 
horses (EIV/1963), and one EIV after 40 years of adaption to its equine host 
(EIV/2003). Two time-points were analysed, corresponding to one being during 
the eclipse phase of replication (4 hours), and one after 24 hours of 
treatment/infection. The gene expression from the IFN-α-treated or infected 
cells will be compared to the RNA present in Mock-infected cells to 
quantitatively measure the increase or decrease of gene transcripts in response 
to the stimulus. 
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4.2. Results 
4.2.1. Proportion of infected E.Derm cells at 4 hours post-infection 
E.Derm cells were infected with two different equine influenza viruses, the 
older EIV/1963 and the newer mammalian adapted EIV/2003. Three separate 
stocks of each virus were grown, so as to allow for the transcriptomic analyses of 
viral quasispecies. Two wells were infected in parallel for each experiment, one 
from which cells were collected for RNA extraction, and one from which cells 
were collected for immunofluorescent staining and quantification using the 
Guava Flow Cytometer. Samples were chosen with similar percentage of infected 
cells, so as to allow for the most unbiased comparison between the two viruses 
(i.e. if one virus had infected more cells, the transcriptome would be affected 
differently when compared to a virus that had infected fewer cells). Figure 25 
shows the experimental samples that were selected for RNA extraction and 
sequencing. For EIV/1963, the average percentage of infected cells was 45.8%, 
and for EIV/2003 it was 46.2%. 
 
 
Figure 25: Percentage of infected E.Derm cells with both EIVs at 4 hours post-infection. Infected 
cells were measured using the Guava Flow Cytometer. Experiments were repeated independently 
three times; error bars indicate the mean with range of the values. 
 
4.2.2. RNA Quantification and Integrity 
The RNA extracted from the Mock, INF-α treated, and EIV-infected E.Derm cells 
were measured using a Qubit to check the RNA Integrity Number (RIN). Only 
samples with an RIN of over 8 were accepted for sequencing. The lowest RIN 
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value was 9.8, with five samples having a RIN of 9.9, and seventeen samples 
with a RIN of 10.  
 
Table 2: Information regarding the samples sent for sequencing, RIN value and concentration of 
RNA is provided. 
  
RNA 
Integrity 
Number 
Concentration    
(ng/µl) 
  
M
oc
k 
4h
ou
rs
 
Repeat 1 10 83.6 
Repeat 2 10 86.3 
Repeat 3 10 144 
IF
N
-a
 
4h
ou
rs
 
Repeat 1 10 62.7 
Repeat 2 10 94.8 
Repeat 3 10 168 
EI
V/
19
6
3 
4h
ou
rs
 
Repeat 1 10 64.7 
Repeat 2 10 116 
Repeat 3 10 181 
EI
V/
20
0
3 
4h
ou
rs
 
Repeat 1 10 71.2 
Repeat 2 10 110 
Repeat 3 10 171 
M
oc
k 
24
ho
ur
s Repeat 1 10 91.7 
Repeat 2 10 156 
Repeat 3 9.9 242 
IF
N
-a
 
4h
ou
rs
 
Repeat 1 10 67.2 
Repeat 2 10 126 
Repeat 3 9.9 186 
EI
V/
19
6
3 
4h
ou
rs
 
Repeat 1 9.9 79.7 
Repeat 2 9.9 57.5 
Repeat 3 9.7 109 
EI
V/
20
0
3 
4h
ou
rs
 
Repeat 1 9.9 129 
Repeat 2 10 114 
Repeat 3 9.8 148 
 
4.2.3. Kraken results after RNASeq 
Kraken is a tool that provides the information of how many reads align to 
pathogens, indicating contamination levels within the samples. These pathogens 
consist of bacteria, viruses, and archaea. Across the replicates and different 
conditions, there was a varying percentage of reads that were assigned as 
belonging to pathogens.  
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For Mock-infected and IFN-α-treated cells at both 4 hours and 24 hours there 
was were no hits with pathogens (Figures 25-30 and 37-42). At 4 hours post-
infection EIV/1963 had 0.8%, 1% and 2% of unaligned reads mapped to viruses 
(Figures 31-33). Of these reads, 99%, 99% and 100% mapped to IAV, 
respectively. Similarly for EIV/2003, 0.3%, 0.2% and 1% of unmapped reads 
mapped to viruses (Figures 34-36). However, of these hits 90%, 91% and 98% 
mapped to IAV, respectively. The majority of the rest of the hits aligned to 
RD114 Retrovirus – 6%, 7% and 2% respectively. 
 
When analysing the unaligned reads at 24 hours post-infection, Kraken assigned 
2%, of all three repeats of EIV/1963-infected samples to virus (Figures 43-45). 
Of these, 98%, 98% and 99% were assigned to IAV respectively. However, another 
0.9%, 1% and 0.5% were assigned to Orthoretrovirinae respectively. For EIV/2003-
infected samples at 24 hours 0.7%, 0.6% and 0.9% of unassigned reads were 
mapped to viruses, with 98%, 97% and 96% of these hits aligning to IAV 
respectively (Figures 46-48). Again, some hits aligned to RD114 Retrovirus – 2%, 
2% and 3% respectively. 
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Figure 26: All unmapped sequenced reads from Mock 4 hour (Replicate 1) were processed with 
the Kraken tool. Image shows the level of reads aligned to pathogens: first a summary, and then 
a closer analysis of the reads aligned to viruses. 
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Figure 27: All unmapped sequenced reads from Mock 4 hour (Replicate 2) were processed with 
the Kraken tool. Image shows the level of reads aligned to pathogens: first a summary, and then 
a closer analysis of the reads aligned to viruses. 
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Figure 28: All unmapped sequenced reads from Mock 4 hour (Replicate 3) were processed with 
the Kraken tool. Image shows the level of reads aligned to pathogens: first a summary, and then 
a closer analysis of the reads aligned to viruses. 
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Figure 29: All unmapped sequenced reads from IFN-α 4 hour-treated (Replicate 1) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 30: All unmapped sequenced reads from IFN-α 4 hour-treated (Replicate 2) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 31: All unmapped sequenced reads from IFN-α 4 hour-treated (Replicate 3) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 32: All unmapped sequenced reads from EIV/1963 4 hour-infected (Replicate 1) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 33: All unmapped sequenced reads from EIV/1963 4 hour-infected (Replicate 2) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 34: All unmapped sequenced reads from EIV/1963 4 hour-infected (Replicate 3) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 35: All unmapped sequenced reads from EIV/2003 4 hour-infected (Replicate 1) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 36: All unmapped sequenced reads from EIV/2003 4 hour-infected (Replicate 2) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 37: All unmapped sequenced reads from EIV/2003 4 hour-infected (Replicate 3) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 38: All unmapped sequenced reads from Mock 24 hour (Replicate 1) were processed with 
the Kraken tool. Image shows the level of reads aligned to pathogens: first a summary, and then 
a closer analysis of the reads aligned to viruses. 
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Figure 39: All unmapped sequenced reads from Mock 24 hour (Replicate 2) were processed with 
the Kraken tool. Image shows the level of reads aligned to pathogens: first a summary, and then 
a closer analysis of the reads aligned to viruses. 
Mock
24 hours 
Replicate 2 
Su
m
m
ar
y 
Vi
ru
se
s 
Chapter 4: Comparative transcriptomics of two viruses 
 
111 
 
Figure 40: All unmapped sequenced reads from Mock 24 hour (Replicate 3) were processed with 
the Kraken tool. Image shows the level of reads aligned to pathogens: first a summary, and then 
a closer analysis of the reads aligned to viruses. 
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Figure 41: All unmapped sequenced reads from IFN-α 24 hour-treated (Replicate 1) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 42: All unmapped sequenced reads from IFN-α 24 hour-treated (Replicate 2) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 43: All unmapped sequenced reads from IFN-α 24 hour-treated (Replicate 3) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 44: All unmapped sequenced reads from EIV/1963 24hour-infected (Replicate 1) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 45: All unmapped sequenced reads from EIV/1963 24hour-infected (Replicate 2) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 46: All unmapped sequenced reads from EIV/1963 24hour-infected (Replicate 3) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 47: All unmapped sequenced reads from EIV/2003 24hour-infected (Replicate 1) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 48: All unmapped sequenced reads from EIV/2003 24hour-infected (Replicate 2) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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Figure 49: All unmapped sequenced reads from EIV/2003 24hour-infected (Replicate 3) were 
processed with the Kraken tool. Image shows the level of reads aligned to pathogens: first a 
summary, and then a closer analysis of the reads aligned to viruses. 
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4.2.4. Data characterization (MDS, Pearson Cor, Hierarchical clustering) 
The overall transcriptomic profile of the four conditions – Mock-infected, IFN-α 
treated, EIV/1963-infected and EIV/2003-infected were investigated using 
different distance-based metrics. Multidimensional Scaling (MDS) was first used 
to examine the Euclidian distances between each transcriptomic profile in two 
dimensions. As can be seen from Figure 50 (A), a small triangle indicates 4 hours 
post-infection samples, and a small circle indicates 24 hours post-infection 
samples. When samples have a similar transcriptomic profile, they will have a 
smaller Euclidian distance to one another, and are therefore found closer 
together. The opposite is true when the samples become divergent, the 
Euclidian distance between them increases. Figure 50 (B) shows the sample 
variation explained by Principle Component (PC) Analysis, and demonstrates how 
PC1 explains much larger variation than PC2. Therefore, the distance 
horizontally has a bigger significance than vertical distances.  
 
At 4 hours post-infection Mock-infected and IFN-α treated cells are most similar 
to each other, with a very small Euclidian distance on the PC1 axis. According to 
the MDS plot, EIV/1963 is more similar than EIV/2003 to Mock-infected samples 
when studied using PC1.  
 
When using MDS to study the variation between the samples at 24 hours post-
infection, both Mock-infected and IFN-α treated cells have moved slightly on the 
plot, showing that they have changed slightly when compared to their placement 
at 4 hours post-infection. They were again very close to each other, meaning 
that in comparison to the other samples, they were very similar to each other. 
Both EIV viruses produced infections with very distant Euclidian distances when 
analyses using MDS. The virus with the largest distance along the PC1 axis from 
the Mock-infected sample was EIV/1963. This means that the transcriptomic host 
responses to the two EIV viruses were different overall.  
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Figure 50: (A) Transcriptomic responses are represented using nonparametric Multidimensional 
Scaling (MDS) at 4 hours and 24 hours post-infection. Euclidian distance was calculated using the 
whole normalized transcriptomic data, such that proximity indicates likeness, whereas distance 
indicates variation, of gene expression profiles. (B) Graph showing variance depending on 
Principal Component. (C) Hierarchical clustering of Mock, IFN-α treated and EIV infected 
samples. Distances were calculated using Pearson correlation distance. (D) Distance between 
Mock-infected samples and IFN-α treatment or EIV-infected samples. The Pearson correlation 
distance (Pearson cor distance) was calculated as 1 - Pearson correlation coefficient calculated 
using normalized transcriptomic data.  
 
 
To further investigate the Euclidean distances (based upon the transcriptomic 
data), hierarchical clustering was used (Figure 50, C). The hierarchical clustering 
confirmed that the Mock-infected and IFN-α treated transcriptomic profiles were 
very similar at both 4 hours and 24 hours post-infection. In addition, the 
clustering demonstrated that EIV/1963 and EIV/2003 infections were more 
similar to each other than to the Mock-infected and IFN-α treated conditions. 
The EIV-infected samples were very distant from the other samples at 24 hours 
post-infection, supporting the evidence from the other plots. 
 
To determine whether the host responses to IFN-α treatment or EIV-infection 
were closer to the Mock-infected transcriptome, we measured the 
transcriptomic distance between the samples of each condition at both time-
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points (Figure 50, D). The IFN-α treated samples had a very small Pearson cor 
distance from the Mock-infected condition (0.0086 and 0.0143 at 4 hours and 24 
hours post-infection, respectively). Infection with either EIV viruses had much 
larger distances than the IFN-α treatment. The transcriptomic response of 
EIV/1963 infection compared to the Mock-infected transcriptome was the larger 
of the two viruses. The Pearson cor distance for EIV/1963 was 0.13 and 0.65 at 4 
hours and 24 hours post-infection, respectively, as compared to 0.12 and 0.55 at 
4 hours and 24 hours post-infection, respectively, for infection with EIV/2003. 
 
4.2.5. A Log2FC value of 0.58 is chosen as the threshold for selecting 
differentially expressed genes for analysis  
Using an algorithm such as CuffDiff2 to interpret the RNASeq results produces a 
large list of DE genes. The DE genes are produced for each condition, where the 
sample is compared to the Mock-infected results at the same time-point. 
Comparisons are between samples within a repeat, rather than the average 
values for all repeats. These must be narrowed down to study the most 
significantly expressed DE genes. A Q value threshold of ≤0.05 was used to select 
a list of genes. 
 
A threshold of Log2FoldChange (Log2FC) was investigated by creating lists of DE 
genes with a Log2FC cut-off of 0.58, 1 and 1.58. These lists of genes were 
plotted to examine how the thresholds affected the numbers of DE genes (Figure 
51, A). There was a large difference in the number of DE genes after infection 
with EIV/1963 between setting the Log2FC cut-off at 0.58 and 1. These large 
differences implied that there were a large number of the DE genes of EIV/1963 
infection that had a Log2FC value of between 0.58 and 1. The lists of genes were 
also entered into Ingenuity Pathway Analysis (IPA) to analyse the Core Pathways 
that were affected. As can be seen from Figure 51 (B) the number of pathways 
affected decreased, with lower P values, upon increasing the Log2FC threshold. 
Therefore for all further analyses, a Log2FC threshold of 0.58 (1.5 Fold Change) 
was chosen as the threshold for selecting the DE genes to study.  
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Figure 51: (A) The number of differentially expressed (DE) genes upon application of different 
Log2FC thresholds. (B) The top 10 Canonical Pathways highlighted by IPA with the different 
thresholds applied to the list of DE genes at 4 hours. 
 
4.2.6. The number of DE genes between conditions varies greatly 
The number of DE genes for each of the conditions varied greatly depending on 
whether the cells were treated with IFN-α or infected with an EIV. The 
transcriptome was also dependent upon time; a much larger number of DE genes 
reported for the infected cells at 24 hours post-infection. As can be seen from 
Figure 52, the number of DE genes upon IFN-α treatment decreased from 4 to 
24 hours post-treatment (262 to 216).  
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Figure 52: (A) Number of Differentially Expressed (DE) genes for each of the conditions with the 
Log2FC values shown. The number of upregulated and downregulated DE genes is shown with up 
and down arrows. (B) Venn diagrams showing the number of DE genes for each condition. 
Numbers in red correspond to upregulated DE genes, and numbers in blue to downregulated. 
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The DE genes for each condition were compared using Venn diagrams. As can be 
seen from Figure 52, there were 66 shared upregulated genes for the three 
conditions at 24 hours post-treatment, as opposed to only 9 shared upregulated 
genes at 4 hours. There were also 14 downregulated shared genes at 24 hours 
post-treatment, and none at 4 hours. EIV/2003 shared more genes with IFN-a 
treated cells at both 4 and 24 hours post-treatment, as opposed to EIV/1963-
infected cells.  
 
When analysing the shared DE genes between the two virus infections, there was 
a greater quantity of shared downregulated DE genes, as opposed to 
upregulated, at both 4 hours post-infection (38 downregulated, 23 upregulated) 
and 24 hours post-infection (3,997 downregulated, 702 upregulated).  
 
4.2.7. E.Derm interferome is dynamic over time 
The interferome of the horse has not been well-characterised, with many genes 
not annotated or unknown. E.Derm cells provide the in vitro system in which to 
fully investigate the Interferon Stimulated Genes (ISGs) produced upon 
treatment with 1,000 UI/ml Universal IFN-α. The two time-points of 4 hours and 
24 hours post-treatment allow the study of a dynamic change in the cellular 
interferome. Cells were collected, RNA extracted, and the transcriptome of the 
treated cells was compared to the transcriptome of control cells at the same 
time-point so as to highlight the DE genes.  
 
The DE genes were plotted on a heat map for the two time-points of IFN-α 
treatment (Figure 53). The interferome didn’t appear static, but was dynamic 
and changed over the increase of treatment time. It was possible to observe 224 
uniquely DE genes over the course of both time-points (135 and 89 for 4 hours 
and 24 hours post-treatment, respectively). When considering the 
downregulated DE genes, there were only eight of these at 4 hours post-
treatment (including S1PR1, NR4A2, PER1 and NFATC2), whereas there were 
twenty-four downregulated DE genes at 24 hours post-treatment (including ND5, 
SACS, USF3 and PYGO1). 
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The response of the cells to the exogenous IFN-α developed over the time 
difference of 20 hours (Figure 53). The number of genes that had a Log2FC of 
infinity decreased from eight to three with the genes that were no longer 
expressed being XAF1, SECTM1, TLR3, GBP5 and CCL13. However, it was 
important to notice that of the three DE genes that had an expression fold 
change of infinity, they had a higher Fragments Per Kilobase of transcript per 
Million mapped reads (FPKM) value at 24 hours post-treatment as opposed to 4 
hours. For example, PLAC8, Mx2 and BST2 all increased their FPKM value at 24 
hours post-treatment from 18.70 to 85.46, 11.83 to 20.82, and 2.11 to 15.65 
respectively. The two viruses share 127 DE genes, with well-known interferon 
stimulated genes (ISGs) such as ISG15, IRF9 and PML all being upregulated. 
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Figure 53: Heat map of Differentially Expressed (DE) genes after 4 and 24 hours IFN-α 
treatment. Upregulated DE genes are shown in red, downregulated DE genes are shown in blue. 
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4.2.8. Gene categories 
The transcriptomic analysis for each of the virus infections produced an 
extremely large list of DE genes. At 24 hours post-infection, there were many 
thousands of genes highlighted for both viruses (Figure 54). These genes were 
categorised into their function using gene ontology (GO) information.  
 
Figure 54 shows the DE genes that were assigned to specified GO categories 
with their accompanying Log2FC value. The specified GO categories were defined 
using descriptive terms returned from Ensembl BioMart. 
 
The difference between the two viruses was more obvious at 4 hours as opposed 
to 24 hours post-infection, repeating what was already shown (Figure 54). In 
comparison to EIV/2003, more genes were downregulated by the EIV/1963 virus 
in each of the categories at both time-points. For example, in the “Cytoskeleton 
or Transport” category, EIV/1963 downregulated 418 genes as compared to 22 
for EIV/2003 at 4 hours post-infection. At 24 hours post-infection, the number of 
downregulated genes for “Cytoskeleton or Transport” increases to 2256 and 2050 
for EIV/1963 and EIV/2003 respectively. These results demonstrate that 
EIV/1963 downregulated the normal cellular functions much more quickly than 
EIV/2003.  
 
The converse is also true when studying the upregulated DE genes. EIV/2003 
caused higher numbers of these genes to be upregulated in almost all the 
categories as compared to EIV/1963. The exception is the “Unknown function” 
category where EIV/1963 and EIV/2003 upregulate 28 and 19, and 488 and 409 
DE genes at 4 hours and 24 hours post-infection, respectively.  
 
For the “Immune Response” category, differences between EIV/1963 and 
EIV/2003 were especially apparent at 4 hours post-infection. EIV/1963 
downregulated 127 DE genes, as compared to 6 DE genes for EIV/2003. In 
comparison, when looking at the upregulated DE genes categorised in “Immune 
Response”, the older EIV/1963 upregulated 14 DE genes, when EIV/2003 
upregulated 23. 
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Figure 54: Differentially Expressed (DE) genes categorised based upon their Gene Ontology. 
Categories were specified based upon search terms returned from the Biomart tool (ensembl). 
Log2FC values are provided, red is upregulated and blue is downregulated. All DE Genes were 
counted for all categories they fell into. The overall total of DE genes found in each category 
(upregulated and downregulated) is provided. 
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treatment, EIV/1963 and EIV/2003 infection) at 4 and 24 hours post-treatment 
(Figure 55). 
 
At 4 hours post-treatment, IPA shows that EIV/1963 downregulated more genes 
in the IFN pathway than cells infected with EIV/2003 (Figure 55). However, the 
two viruses shared many of the same upregulated IFN genes: IFNα/β, IRF9, IFIT1, 
Mx1, G1P2 and IFIT3. The downregulated DE genes by EIV/1963, which do not 
appear to be affected by EIV/2003, were STAT2 and TAP1.  
 
When the IFN pathway at 24 hours post-infection was examined, SOCS1 was 
upregulated by EIV/1963 but not by EIV/2003. Conversely, IFNRα, IFNR1, TC-PTP 
and PIAS1 were all downregulated by EIV/1963, but not shown to be affected by 
EIV/2003. Instead, EIV/2003 downregulated JAK1 and TYK2 while EIV/1963 did 
not affect these DE genes and both of the viruses downregulated DRIP150. When 
studying the shared upregulated genes by the two viruses, IFNα/β, IRF9, IFIT1, 
Mx1, G1P2, IFIT3 also were shared at 4 hours post-infection. IFI35, OAS1, and 
G1P3 were newly shared upregulated genes for 24 hours post-infection. 
 
When the transcriptome of the IFN-α treated cells was studied with IPA, the 
exact same genes were highlighted as being upregulated. All of the upregulated 
genes of the EIV infections were also shared by IFN-α treatment at 4 hours. The 
extra genes upregulated by IFN-α that were not upregulated by the virus 
infections at 4 hours post-infection were STAT1, STAT2, JAK2, TAP1, SMB8, 
IFI35, OAS1, G1P3 and PSMB8. The upregulated genes shared across all three 
conditions were IRF9, IFIT1, Mx1, G1P2 and IFIT3. At 24 hours post-infection the 
number of shared upregulated genes increased to include IFI35, OAS1 and G1P3. 
The only genes highlighted by IPA that were uniquely increased by IFN-α 
treatment were STAT1, STAT2, JAK2, TAP1, SMB8 and PSMB8. However, at 4 
hours post-infection the EIV/1963 virus downregulated TAP1 and STAT2. Overall, 
EIV/1963 downregulated more genes in the IFN pathway than EIV/2003 especially 
at 4 hours post-infection.      
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Figure 55: IPA software was used to highlight the affected proteins in the IFN signaling pathway 
from the list of DE genes for IFN-α treated cells. Both 4 hours and 24 hours results are shown. 
See Figure 58 for legend. 
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Figure 56: IPA software was used to highlight the affected proteins in the IFN signaling pathway 
from the list of DE genes for EIV/1963-infected cells. Both 4 hours and 24 hours results are 
shown. See Figure 58 for legend. 
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Figure 57: IPA software was used to highlight the affected proteins in the IFN signaling pathway 
from the list of DE genes for EIV/2003-infected cells. Both 4 hours and 24 hours results are 
shown. See Figure 58 for legend. 
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Figure 58: Ingenuity Pathway Analysis legend for pathway analyses (Figure 55, Figure 56, Figure 
57, Figure 59, and Figure 60). 
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4.2.10. The eIF2 signaling pathway is affected differently by the two 
equine influenza viruses 
The Eukaryotic Initiation Factor 2 (eIF2) signalling pathway was compared 
between both evolutionary distinct EIVs. IPA software was used to predict which 
proteins in the pathway would be affected, either by being up- or 
downregulated. 
 
At 4 hours post-infection the eIF2 signaling pathway wasn’t affected by EIV/2003 
and was, therefore, not highlighted by IPA. However, EIV/1963 did affect some 
of the proteins in this pathway as is shown in Figure 59. The older virus 
downregulated eleven proteins, and upregulated none. 
 
When comparing the two viruses at 24 hours (Figure 60), and which proteins 
they downregulated in the eIF2 signaling pathway, EIV/2003 uniquely 
downregulated ATF5 and eIF2β, whereas EIV/1963 downregulated ten proteins 
(CHOP, PERK, HSPA5, GCN2, eIF2α, eIF3, HR1, eIF5, PDK1, ERK1, eIF2β) that the 
younger virus did not. The two viruses shared nine proteins that were 
downregulated (TRIB3, SREBP1, XIAP, NOX4, PP1C, eIF4G, PI3K, INSR, SOS). 
 
By observing the upregulated proteins at 24 hours post-infection, it was 
apparent that EIV/2003 upregulated many more proteins as compared to 
EIV/1963 (for example AFT3). The two viruses both upregulated five shared 
proteins (G-actin, CYCLIND1, 40s ribosomal subunit, RAS and 60s ribosomal 
subunit). The evolutionary older virus, EIV/1963, only upregulated one unique 
protein (AKT), whereas EIV/2003 upregulated seven (PKR, GADD34, ATF3, N-
MYC, C-MYC, VEGFA, eIF3). 
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Figure 59: IPA software was used to highlight the affected proteins in the eIF2 signaling pathway 
from the list of DE genes for IFN-α treatment, EIV/1963-infected and EIV/2003-infected. The 
results for 4 hours are shown. See Figure 58 for legend. 
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Figure 60: IPA software was used to highlight the affected proteins in the eIF2 signaling pathway 
from the list of DE genes for IFN-α treatment, EIV/1963-infected and EIV/2003-infected. The 
results for 24 hours are shown. See Figure 58 for legend.  
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4.3. Discussion 
The way a virus controls the cellular machinery of a host changes over time. 
These changes over time are not only due to viral evolution, but also due to the 
evolution of the host. The evolution of the virus and host together is often 
referred to as an “arms race”, where both the virus and the host are trying to 
evolve more rapidly and efficiently than the other (Daugherty & Malik 2012). To 
date, studies into how the evolution of influenza affects viral control of the host 
cell are lacking. 
 
Two evolutionary distinct equine influenza viruses (EIVs) were selected to 
study in E.Derm cells. They had previously been shown in Chapter 3 to grow very 
differently in the equine cells (Figure 13). The newer evolutionary virus 
(EIV/2003) grew much more efficiently and to considerably higher titres than the 
older evolutionary virus (EIV/1963). When both viruses were grown in cells pre-
treated with 1,000 UI/ml of IFN-α, EIV/1963 was much more negatively affected 
than EIV/2003 (Figure 21). The difference in how pre-treatment affected the 
EIV/1963 and EIV/2003 viruses formed the hypothesis that the two EIVs were 
manipulating the host response in different ways, with the more adapted virus 
(EIV/2003) being able to overcome IFN-α treatment. 
 
RNASeq is a relatively novel tool that allows for the study of the 
transcriptome of cells exposed to different conditions (Josset et al. 2014; Simon 
et al. 2015; Morrison et al. 2014). In this chapter transcriptomics was used to 
study an equine dermal (E.Derm) cell line upon IFN-α treatment, and infection 
with two evolutionary distinct EIVs. 
 
Kraken is a useful tool to study the unassigned sequencing reads after 
alignment to a genome. It allows for the analysis and identification of possible 
contaminants. This result was reassuring as it was evidence that the samples had 
not become contaminated with other bacteria or viruses during culture, 
experimental infection or RNA extraction. For the samples infected with EIV, it 
was expected that some of the reads for align with IAV as the cells were 
infected with this virus. However, it was interesting to note that at both 4 hours 
and 24 hours post-infection that a higher percentage of reads mapped to IAV for 
infection with EIV/1963. The reason for this could be that EIV/1963 possibly 
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produces a higher number of RNA transcripts than EIV/2003. More investigation 
could be carried out to analyse these transcripts separately. Another point of 
interest was that quite a few of the unassigned read for infection with EIV/2003 
that aligned to viruses were shown to be a match for RD114 Retrovirus. This 
observation was repeated across time-points, and independent repeats just for 
EIV/2003, which would suggest that this was not a contamination issue. A 
possible reason could be that some of EIV/2003 transcripts can also be aligned to 
the genome of the RD114 Retrovirus. This phenomenon was also observed at 24 
hours for infected cells with EIV/1963 – a number of reads mapped to 
Orthoretrovirinae. Possibly there are transcripts produced by EIV/1963 later in 
infection that align to Orthoretrovirinae, as there were no reads aligned to this 
other virus at 4 hours post-infection. 
 
The sequencing data were studied using distance-based metrics in order 
to ascertain how similar the experimental replicates were. The Mock-infected 
and IFN-α treated cells were shown to be much more similar to each other than 
the EIV-infected samples at both 4 and 24 hours post-infection. At 24 hours post-
infection, the EIV/1963 and EIV/2003 samples were very distant to the Mock-
infected samples (Figure 50, A). The similarity between the EIV infected cells was 
confirmed using hierarchical clustering and Pearson cor distance, to show that 
the EIV-infected cells clustered together and had a greater distance to the Mock-
infected cells, as opposed to the IFN-α treated cells that were very close to the 
Mock samples (Figure 50, C+D). Overall, these results demonstrate that the host 
response to infection with EIVs is highly specific to each virus, although these 
viruses shared more similarities than to the Mock-infected or IFN-α 
transcriptomic profiles. 
 
After RNASeq was carried out, the sequencing reads were processed using 
the CuffDiff2 pipeline to produce a list of upregulated or downregulated genes in 
the treated/infected cells, when compared to the gene transcripts expressed in 
the control cells. These genes are referred to as differentially expressed (DE) 
genes. When determining which of the DE genes to select for further analyses, it 
was important to use thresholds to choose the most important genes for study. 
Therefore, a Q value threshold of ≤0.05 was used to select the lists of genes. A 
further threshold was used for the Log2FoldChange (Log2FC) range. The effect of 
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varying the Log2FC threshold was investigated by creating lists of DE genes with 
a Log2FC cut-off of 0.58, 1 and 1.58. As can be seen from Figure 51, the number 
of DE genes began to decrease after a Log2FC value of 1 was applied. When the 
lists of DE genes for each of the thresholds for the data at 4 hours post-infection 
was analysed using Ingenuity Pathway Analysis (IPA) software, there was an 
obvious decrease in the number of Canonical Pathways highlighted when a 
Log2FC threshold of 1 or 1.5 was selected.  This loss of IPA data was considered 
to be an important loss of information and therefore, a Log2FC value of 0.58 was 
selected as the threshold. For the rest of the chapter any analyses were carried 
out using only DE genes with a Log2FC value larger than 0.58. 
 
It is important to note that the Log2FC threshold can vary in the literature 
(0.58 (Eschbaumer et al. 2016), 1 (Morrison et al. 2014) and 1.58 (Josset et al. 
2014)) and that this can affect any conclusions made upon investigation of the 
list of DE genes. To this end, the chosen thresholds, the motivations for their 
choice, and their possible effects were stated. As the world of RNASeq is still 
relatively new, this is something that the field will have to reach conclusions on. 
What are considered liberal and strict thresholds, and how should researchers 
check whether the correct filters are being applied? These questions are 
something that will need to be investigated further and may take many years 
before the research community reaches an agreement. 
 
The number of DE genes was plotted for each of the conditions, with the 
number of upregulated and downregulated DE genes highlighted by arrows 
(Figure 52, A). The transcriptome for the IFN-α treated cells remained under 
300 genes for both time-points studied (4 hours and 24 hours). The stasis of the 
IFN-α transcriptome is in contrast to the dynamic response of the two EIV-
infected transcriptomes over the two time-points. The number of DE genes 
increased considerably for both viruses, however EIV/1963 affected many more 
genes than EIV/2003 at 4 hours post-infection (1,100 and 131 respectively). The 
stasis of the IFN-α treatment demonstrated that the cells were already in a 
highly responsive state with just 4 hours of treatment. 
 
Venn diagrams were a useful tool for indicating the genes shared by each 
condition, as well as allowing for the identification of unique genes (Figure 52, 
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B). Interestingly, at both the 4 hours and 24 hours time-points, all three 
conditions upregulated some IFN stimulated genes (ISGs) that have been shown 
to be important in relation to influenza infection. These important genes 
included IRF9, ISG15 and MX1. Four hours post-infection the EIV/1963 virus 
downregulated a large number of genes (997). Conversely, EIV/2003 appeared to 
be more selective in the genes that it targets for downregulation, targeting 
LARP6 (function includes RNA binding and nucleotide binding (Fagerberg et al. 
2014)) and CCXC5 (function includes sequence-specific DNA binding and signal 
transducer activity (Fagerberg et al. 2014)) among others. EIV/2003 tolerated 
five genes that were upregulated by IFN-α, one of these includes OAS2 – a gene 
that has been documented as being important for the innate response to viral 
infection (Hovanessian et al. 1987). At the time-point of 24 hours, the three 
conditions shared a large number of upregulated genes. The reason for a high 
number of upregulated genes being shared is that the IFN response has been 
stimulated by both infections at this later time-point, and a lot of the genes 
shared are also turned on by IFN-α treatment. 
 
While the number of DE genes for IFN-α treatment did not change over 
the two time-points, when upregulation and downregulation of the DE genes was 
studied more closely using a heat map (Figure 53), the actual DE genes were 
vastly different, even though the number of DE genes stayed relatively similar. 
The analysis of two time-points allowed for the dynamic nature of the response 
of the E.Derm to IFN-α to be evaluated. At 24 hours post-treatment there were 
more downregulated genes than at 4 hours. The Fragments Per Kilobase of 
transcript per Million mapped reads (FPKM) value of some of the DE genes had 
increased greatly. The results from this chapter have shown the interferome of 
E.Derm cells to be dynamic over time, rather than a static event. Two time-
points of IFN-α treatment were compared (4 and 24 hours) and the number of 
upregulated and downregulated DE genes (as compared to Mock-infected) 
decreased at the later time-point. This is a phenomenon that has not been 
regularly studied. The results of this chapter agreed with a study that 
investigated IFN treatment over time of Primary Human Hepatocytes (PHH) (Jilg 
et al. 2014). Genes such as IFIT3, IFI1 and Mx1 were shown to be dynamic and 
had a lower Log2FC value at 24 hours post-treatment. In the study by Jilg et al. 
(Jilg et al. 2014), they shared some of the genes that increased expression at 8 
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hours post-treatment to then decrease at 24 hours post-treatment. However, 
there wasn’t complete concordance between this study and the current Chapter, 
genes such as Mx2 were shown to increase their FPKM value here and Jilg et al. 
found that the gene decreased at 24 hours. Overall, these findings show that 
treatment of cells with IFN-α produces a kinetic expression of ISGs that changes 
over time. 
 
Categories were created based on Gene Ontology (GO) from the online 
tool Biomart (Ensembl), and the DE genes for the virus-infected conditions were 
analysed to see which category they fell into (Figure 54). The largest 
differences were observed at 4 hours post-infection, with EIV/1963 
downregulating many genes involved with gene expression, as opposed to 
EIV/2003. EIV/1963 downregulated many more genes than EIV/2003 for all of the 
eight categories analysed. In addition, the downregulation of more genes by 
EIV/1963 was true in almost all the categories at 24 hours post-infection, but the 
difference wasn’t as marked as at 4 hours. Therefore, EIV/1963 was controlling 
the host cellular response to infection in a different way than EIV/2003 
especially at 4 hours post-infection. The older, less evolutionary adapted, virus 
appeared to shut down the cellular functions of the host much faster than 
EIV/2003. The stronger response by the virus may be required because the virus 
has not adapted more efficient ways of hiding from the host immune response. It 
may be that as EIV became more adapted to its host, it was able to target the 
specific genes required for successful concealment and replication of the virus 
and didn’t require the unconditional downregulation of DE genes. 
 
 IPA was used to study the IFN signalling pathway, and predict how the 
three conditions (IFN-α treatment, EIV/1963-infection and EIV/2003-infection) 
affected the proteins within this pathway (Figure 55). It was interesting that 
although Jilg et al. (Jilg et al. 2014) showed that the IFN-α transcriptome was a 
dynamic event, the proteins highlighted in the IFN signalling pathway were the 
exact same at 4 hours and 24 hours post-treatment. The kinetic genes in the IFN-
α treated cells appear involved in cellular aging and metabolic processes, while 
the core ISGs remain present across both time-points. The genes that were 
upregulated by IFN-α treatment were crucial during the interferon response 
(e.g. STAT1, STAT2, JAK2) and therefore it is of interest that these genes were 
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not upregulated upon infection with an IAV. In fact, EIV/1963 downregulated 
STAT2 at 4 hours post-infection, which could be the way that the older virus is 
manipulating the interferon response to infection. STAT1 isn’t phosphorylated 
without STAT2, and as this process begins the cascade to turn on ISGs it is 
beneficial for EIV/1963 to target this gene for degradation (Qureshi et al. 1996). 
It is of interest that EIV/2003 downregulated JAK1 at 24 hours post-infection, 
targeting a gene that is before STAT2 in the IFN-signaling cascade (Uetani et al. 
2008). 
 
At 24 hours post-infection the two signalling pathways for eIF2 appeared 
similar, but there were important differences (Figure 60). The formation of the 
heterotrimer consists of three subunits: eIF2α, eIF2β and eIF2γ. EIV/1963 acts to 
disrupt the eIF2 signalling pathway by downregulating the eIF2α subunit, as 
opposed to EIV/2003, which downregulates the eIF2β subunit. By decreasing 
expression of the eIF2α subunit, EIV/1963 is limiting the production of the eIF2 
complex, which is required for the initiation of mRNA translation. Therefore, 
this inhibits protein synthesis. The phosphorylation of eIF2α by PKR is one of the 
most frequent targets by invading viruses to regulate the host cell (22, 23). 
EIV/2003 manipulated the eIF2 signaling pathway in a different way by targeting 
the eIF2β subunit for downregulation. Figure 60 also demonstrates that 
EIV/2003 infection caused the upregulation of PKR (Protein Kinase R). As the PKR 
molecule is very important for downstream antiviral responses, it would be 
interesting to study the formation of PKR protein to see if the virus targets this 
molecule post-translationally. 
 
One of the molecules in the eIF2 signaling pathway that EIV/2003 
upregulated, and which was not affected by EIV/1963, was AFT3 (Activating 
Transcription Factor 3) (Figure 60). Contrary to its name, AFT3 suppresses 
rather than activates transcription from promoters with ATF sites. It combats an 
excessive, and potentially damaging, inflammatory response as it regulates both 
inflammatory chemokines and cytokines (Khuu et al. 2007; Chen et al. 1994). 
Therefore, the fact that EIV/2003 upregulated the expression of this gene could 
be one of the reasons to explain why this virus was more efficient at replicating 
in the host cells, and why it can replicate much more efficiently than EIV/1963 
after pre-treatment with IFN-α (Figure 21, D). 
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It is understood that IAVs cause host shutdown in order to replicate within 
a cell (Rivas et al. 2016). Nevertheless, the dynamics of how the host shutdown 
differs between different strains of viruses has not been studied in detail. It has 
been shown that some IAVs are more selective in the degradation of host 
transcripts due to the PA-X protein. A study by Khaperskyy et al. (Khaperskyy et 
al. 2016), demonstrated that PR8 targeted host RNA polymerase II (Pol II) 
transcribed mRNAs, while sparing products of Pol I and Pol III. Two additional 
methods that IAVs can use to shutdown host responses are through inhibition of 
polyadenylation and export of host mRNAs by NS1 (Krug 2015), or RNA Pol II 
degradation by the viral RNA-dependent RNA polymerase (RdRp) (Chan et al. 
2006). In summary, there are three known methods through which IAVs can 
manipulate the host cellular responses, but it is unclear which of these methods 
a virus uses and how this is affected by how well adapted the virus has become 
to its host. A virus that may not have evolved an NS1 that can bind to CPSF30 
(the 30-kDa subunit of cleavage and polyadenylation specificity factor, whose 
function is to carry out in the 3′-end processing of cellular pre-mRNAs, may 
instead depend more heavily upon methods such as PA-X activity or Pol II 
degradation. With RNASeq becoming more developed and refined, it will be 
possible to perform further experiments studying how different evolutionary 
strains of the same IAV manipulate the host response using these different 
methods. 
 
Broadly, some of the differences between how the older EIV and the 
younger EIV control the host response upon infection were dramatic, and yet 
some of them were subtler. This chapter has highlighted these differences for 
two very specific EIVs, and it would be interesting to test different EIVs from 
across the evolutionary time period, to determine whether the method of 
controlling the host transcriptome evolves over time. In addition, it would be 
useful to study additional time-points of infection to observe the dynamic 
change over time. With only having the two time-points of 4 and 24 hours, there 
are a lot changes in the missing 20 hours between that could provide more 
information of how the two viruses control the cell. As this chapter describes an 
observational study, it would be beneficial to further investigate the genes 
highlighted using mechanistic experiments. 
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 Overall, the research carried out in this chapter was to examine the 
equine host response to two evolutionary different EIVs. Transcriptomics was 
used to study the host transcriptome after infection, and compare it to the 
interferome – the transcriptome present in the cells after treatment with IFN-α. 
The two viruses were shown to manipulate the host response in distinct ways, 
with EIV/1963 acting much more strongly than EIV/2003 by downregulating many 
more genes at both 4 and 24 hours post-infection. The less-adapted virus induces 
host shutoff by downregulating as many host proteins as possible, causing more 
cell death (as seen in Chapter 2). Conversely, EIV/2003 appeared more selective 
in the genes that it targeted for downregulation, in both the IFN-response and 
general gene expression. The phenotype of infection didn’t produce a lot of cell 
death, yet much higher viral titres were produced when compared to production 
of EIV/1963 virions. Over the evolution of the two viruses – from first infecting a 
horse, to 40 years later – the virus has adapted to its mammalian host, through 
evolution of all the gene segments. It has become adapted and able to target 
specific cellular functions, replicate in IFN-treated cells, and replicate to high 
titres. These findings were investigated in more detail by Chauché et al. 
((Chauché et al. 2017).  
 
A hypothesis is that as the EIV virus adapted to its equine host it evolved 
to be able to manipulate the cellular response to infection much more 
efficiently and selectively, without having to downregulate many genes 
unconditionally. Of course, much more research must be done to investigate this 
hypothesis and test its strength. But the research described here begins to 
attempt to understand how viruses spanning 40 decades control the same host in 
different ways, and these are important experiments that should be continued 
with other influenza A viruses in other hosts to see if there are similar patterns 
when an avian virus crosses the species barrier and has to adapt to mammals. 
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5.1. Summary of Findings 
Influenza A viruses (IAVs) are viruses that are capable of jumping the host 
species barriers to infect new hosts. Originally viruses of avian origin, infecting 
wild waterfowl, they now infect many different mammals such as pigs, whales 
and humans (Ito et al. 1998; Cheung & Poon 2007). Horses have been 
documented as infected with influenza since 1956, when an IAV was first 
isolated, but it is believed they were infected much longer before this (Sovinova 
et al. 1958). An H3N8 of avian origin was first detected in horses in 1963 and has 
since outcompeted the previous equine influenza virus (EIV) of subtype H7N7, to 
the point where it is now considered extinct.  
 
 One of the most interesting aspects of influenza is the way it can 
manipulate and escape the host immune response allowing it to jump the host 
species barrier and infect a wide range of hosts (Waddell et al. 1963; Lee et al. 
2010; Anthony et al. 2012). The research described in this thesis has 
concentrated on EIV as a model to study the evolution of a virus over time to its 
host. The lessons learned from this study can hopefully be applied to study 
human IAVs and how they adapt over time to human hosts. 
 
 The availability of cells to study influenza infection in vitro is limited, 
especially when considering cells from a specific host such as the horse. There 
are a few human cell lines such as A549 and BEAS-2B, or the widely used MDCK 
cell line (Lee et al. 2010; Gan et al. 2015; Seitz et al. 2012). However, it was 
essential to study the infection kinetics of EIV in an appropriate equine cell line 
in order to reveal the specific host responses to infection. Therefore, Chapter 2 
of this thesis describes the characterization of an equine dermal (E.Derm) cell 
line, specifically for studying infection with IAVs. The infection conditions used, 
and the replication phase of an equine influenza virus (EIV) was determined. 
 
 There was no previous documentation of E.Derm cells being used for 
infection with influenza. The only papers in a literature search were those 
involving equine arteritis virus and equine herpesvirus-1 (McCollum 1986; 
Cullinane et al. 1988; Hasebe et al. 2009; Telford et al. 1992). The conditions to 
grow influenza in vitro usually requires the addition of exogenous proteases for 
the maturation of the HA of the IAVs (Klenk et al. 1975; Seitz et al. 2012). Cell 
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lines can be susceptible to infection with viruses, but this does not necessarily 
mean that they will be permissive and produce new virions. Therefore, one of 
the critical purposes of Chapter 2 was to establish if E.Derm cells were 
permissive to infection with EIVs. An EIV from 2003 (EIV/2003) was used as the 
test virus, and it was shown that E.Derm cells do allow for the successful 
replication of an EIV.  
 
A point of interest was whether the cells would have a selective capacity 
over which IAV would be able to replicate. It is known that after EIV infected 
dogs, and continued to evolve into Canine Influenza Virus (CIV), this new strain 
cannot infect horses (Yamanaka et al. 2010). Hence, a CIV virus from 2009 
(CIV/2009) was used to infect E.Derm cells and was shown to have significantly 
lower replication efficiency when compared to EIV/2003. The finding that 
E.Derm cell lines were selective in the viruses that could replicate efficiently 
was an important result, since it allowed for the investigation into host specific 
barriers that allow some IAVs to replicate more effectively than others. For 
example, MDCK cells were permissive to almost all IAVs and they replicate to 
very high titres in this cell line. So the well-known cell line could not be studied 
for host barriers to infection, as there appears to be very few. The rest of the 
experiments in this thesis were based upon the finding that the E.Derm cell line 
was a relevant equine cell line, and experiments were designed to investigate 
the host barriers. 
 
An additional finding from the experiments described in Chapter 2 
characterising the E.Derm cell line was that an exogenous protease was not 
required for the successful replication of an EIV. The lack of a necessity for 
exogenous protease showed that the HA of the virus must be being cleaved by an 
intrinsic protease present within the E.Derm cells. All further experiments 
within the thesis did not require the presence of an exogenous protease 
(specifically Tosyl Phenylalanyl Chloromethyl Ketone (TPCK)-trypsin). 
 
 The establishment of the E.Derm cell line meant that specific host 
barriers to infection with different IAVs could be analysed. Four IAVs were 
selected for analysis: an avian IAV that has the potential to cross the host 
species barrier and infect horses (AIV/2009), an un-adapted EIV from 1963 when 
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horses were first infected (EIV/1963), an EIV from 2003 after 40 years of 
adaptation to the horse (EIV/2003), and a CIV from 2009 after the virus had 
become adapted to canine rather than equine hosts (CIV/2009) – all of the H3N8 
subtype. 
 
 Chapter 3 of this thesis shows the results from the infections with these 
IAVs in the E.Derm cell line. The overall growth kinetics of the viruses were 
examined and following this, two host barriers were thoroughly investigated: 
susceptibility to pre-treatment with IFN-α, and protease cleavage of the 
haemagglutinin (HA) glycoprotein. To compliment this work, the growth kinetics 
of the viruses were also studied in ex vivo horse trachea in order to compare the 
in vitro results to a more realistic model. The results from the infection in the 
ex vivo system showed that the two EIVs were able to replicate in the system, 
with EIV/2003 replicating more efficiently than EIV/1963. In addition, AIV/2009 
and CIV/2009 replicated to lower titres than the EIV viruses, with AIV/2009 
absent on some days of infection.  
 
 The in vitro infections with the four IAVs demonstrated that the viruses 
had very different phenotypes in relation to cytopathic effects (CPE) in the cells. 
AIV/2009 completely destroyed the monolayer of cells and EIV/1963 also killing a 
lot of cells. Whereas, EIV/2003 produced very little CPE, and CIV/2009 produced 
even less. When TPCK trypsin was added to the cells during infection to provide 
an exogenous protease, the virus that was most positively affected was 
AIV/2009, although CIV/2009 also benefitted. The positive effect of providing an 
exogenous protease suggests that a barrier to these viruses is the availability of 
compatible proteases for the haemagglutinin (HA) glycoprotein of the virus. 
Whereas the two EIVs that are adapted to the equine host were not positively 
affected by the addition of TPCK trypsin. 
 
 The results of pre-treating the E.Derm cells with 1,000 UI/ml of IFN-α for 
24 hours and then infecting with the viruses allowed for the assessment of how 
resilient each virus was to the host immune response. The viruses that were 
most negatively affected by this pre-treatment were AIV/2009 and EIV/1963. 
The high negative affect of pre-treatment on these two viruses was interesting 
since AIV/2009 is an avian virus with no known replication in mammals, and 
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EIV/1963 was isolated at the very beginning of the H3N8 outbreak in horses 
meaning that it had recently been an avian virus. Therefore, these two viruses 
are not adapted to mammals, unlike EIV/2003 and CIV/2009 which have been 
evolving in a mammalian host for decades and were not majorly affected by pre-
treatment with IFN-α. 
 
 Overall, the results from Chapter 3 showed that the four viruses appeared 
to manipulate the cells in different ways. AIV/2009 and EIV/1963 caused more 
CPE while replicating, and therefore seem to aggressively shutdown cellular 
pathways. The equine IAVs have an HA that is efficient at replicating in cells 
with an equine protease, which is particularly interesting in the context of 
CIV/2009 replicating more efficiently with the addition of an exogenous 
protease. Therefore, protease availability may be one of the limiting factors 
that inhibit the canine virus from infecting horses. CIV/2009 appears to have 
evolved in the canine host and adapted to those proteases, and therefore has 
shifted efficiency away from equine proteases. Finally, it appears that the IAVs, 
which have been circulating in mammals for many years and have had time to 
adapt to their immune response, are able to manipulate the host response after 
pre-treatment with IFN-α. In contrast, the infection kinetics of AIV/2009 and 
EIV/1963 decrease when an immune response is already present. 
 
 Following the preliminary investigations carried out in Chapter 3 in 
relation to the growth kinetics and host barriers to infection with a panel of 
IAVs, it was decided to further investigate the two EIVs within the E.Derm cells. 
Transcriptomics was used to study how both viruses differ in their manipulation 
of the host response to infection. In conjunction, other cells were treated with 
IFN-α in order to investigate the equine interferon (IFN) response in infected and 
non-infected cells. 
 
The eclipse phase of EIV infection within E.Derm cells was investigated in 
Chapter 2, and was established as being 7 hours. Therefore, of the two time-
points selected for investigation, one was during the eclipse phase (4 hours), and 
the other was chosen to allow the virus to have several cycles of replication (24 
hours). Transcriptomics was used to analyse the cellular transcripts within the 
cells at these two time-points for four conditions: Mock-infected, IFN-α treated, 
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EIV/1963-infected and EIV/2003-infected. The CuffDiff2 pipeline was used to 
produce lists of Differentially Expressed (DE) genes by comparing the transcripts 
found in each of the conditions to the transcripts in the Mock-infected cells. The 
DE genes were given a value called Log2FoldChange (Log2FC), which could either 
be positive or negative depending on whether the DE gene was upregulated or 
downregulated by the condition. When looking at how similar the samples were 
to each other, distance based metrics were used. It was reassuring to see that 
replicates of each condition were spaced closely to each other, demonstrating 
that there was corroboration between the replicates. The closest two conditions 
were the EIV infected samples.  
 
The equine IFN response has not been studied extremely closely, and so 
there are many equine ISGs that remain uncategorized, as shown by the genes 
that did not have a defined “Gene Name”. The transcriptomics analysis of the 
two time-points showed that the IFN response was dynamic, with many genes 
only differentially expressed at either 4 hours or 24 hours post-treatment. The 
genes that were present at both time-points also changed their expression levels 
within the cells. Overall, the results showed some of the highly expressed genes 
in response to IFN treatment, and these could be analysed further and deemed 
the “core” equine ISGs. 
 
When the cellular pathways affected by infection were both analysed 
using gene ontology, it was shown that the two viruses controlled the host 
cellular responses in different ways. This was most apparent during the eclipse 
phase when EIV/1963 caused host shutdown and downregulated many DE genes, 
whereas EIV/2003 affected far fewer genes at 4 hours post-infection. The two 
viruses also controlled the IFN response in different ways, with EIV/2003 
apparently tolerating the presence of more ISGs than the less adapted EIV/1963. 
The hypothesis at the end of this chapter of results is that the EIV/2003 has had 
many more years to adapt to its equine host and so has become more efficient 
at targeting specific genes for downregulation. Whereas, the EIV/1963 has not 
evolved to replicate efficiently within the host and so must shut down the host 
cellular pathways in a much more aggressive way. 
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5.2. Limitations and Future Directions 
This thesis describes experiments undertaken mainly using the E.Derm cell line 
to study equine host barriers to infection with influenza. It is important to 
discuss the limitations to this research, and possible methods to overcome these 
restrictions to proceed with future directions.  
 
 The first point to address is the equine cell line that was used. It is a 
fibroblast cell line from the dermis of a horse. In mammals, IAVs naturally infect 
the respiratory tract of the host. Therefore, artificially infecting a cell line 
originally from the skin of a horse is not ideal, and it would have been more 
biologically relevant to have a cell line originating from the respiratory tract, 
which at the time was not possible. The Murcia group had also tried to culture a 
primary cell line from the horse trachea with no success. It is important to note 
that the E.Derm cell line had also been extensively passaged, and senesces after 
40 passages according to the information provided by the American Type Culture 
Collection (ATCC) website. For this reason, cells used for experiments in this 
thesis were not kept beyond 30 passages. The ATCC additionally noted that “55% 
of the cells have a chromosome number within + or - 1 of the diploid and modal 
number” with the “modal number = 64; range = 52 to 145”. A highly variable 
chromosome number of the cells can lead to inconsistencies and cellular 
abnormalities. Overall, it would be useful to produce an immortalised equine 
cell line in order to repeat these experiments in a more relevant system, or use 
the ex vivo organ culture system. 
 
 The percentage of cells infected at the time of RNA collection could be 
interpreted as another limitation in two different ways. After a lot of optimising 
the highest percentage of cells infected at 4 hours post-infection was 46%. It 
could be argued that this means that 54% of cells were uninfected and that could 
have dampened the overall transcriptomics signal as they wouldn’t be expressing 
the same genes as infected cells. An additional criticism could be that infecting 
such a high percentage of cells is not something that would occur naturally to a 
host during infection in the wild. Normally during infection with a virus, very few 
virions actually infect a host directly, so having such a high percentage of cells 
infected during the eclipse phase may not reveal the same DE genes as a lower 
impact, slower infection as seen in vivo. It was decided during the course of this 
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thesis to pursue the results using a high percentage of infected cells to increase 
the chance of a unique transcriptomic signal at the short time-point of 4 hours 
post-infection. The high percentage of infected cells meant that the latest time-
point that could be taken was at 24 hours post-infection, as at this point all the 
cells were dying. It would be useful to compare an infection beginning with a 
more realistic percentage of infected cells and to follow the infection over a 
longer time period. Due to time constraints this wasn’t investigated for the 
purpose of this thesis, but could be followed up in the future. 
 
An alternative to transcriptomics of a whole well of cells is to perform 
single cell transcriptomics. This technique is the study of the transcriptome 
within a single cell, and would allow the comparison of different cells and their 
responses. It is reported in the literature that there is a wide variation between 
the responses of cells to stimuli such as infection and treatment with IFN, 
therefore this would be an interesting point to study (Shalek et al. 2013). It 
would also overcome the fact that such a high percentage of cells would have to 
be infected as to have an overall signal, as the infected cells could be selected 
individually. 
 
The number of replicates used in this thesis for the transcriptomics 
analysis (and other infections) was three. As with any biological experiment, it is 
always preferable to have more replicates in order to have a higher statistical 
power. The limitations of statistics were due to the low sample size, as they 
assume that the underlying distribution being sampled is a normal distribution 
and that the variances of the distributions being compared are the same. If more 
time and resources were available, more replicates would have provided 
stronger statistical analyses. This is why a lot of comparisons appear to be non-
significant. It is interesting that for the bioinformatics tools that were analysing 
the cellular transcriptome, it was possible to run these with only one sample, 
but this is highly un-recommended. In the end, three samples were chosen as 
the minimum for this thesis, but it would be good to repeat more replicates, 
potentially decreasing the p-value of any DE genes identified. A higher number 
of replicates was not possible for this research due to time constraints, and the 
sequencing costs, of preparing additional replicates. 
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A drawback to using transcriptomics is that this studies the RNA and gene 
expression of a cell, before the genes were translated into proteins. The overall 
gene expression of a cell does not fully equate with what is present as proteins, 
due to the host cell not translating all gene transcripts. It is also important to 
consider that influenza can cause degradation of gene transcripts before they 
are formed into proteins. Transcriptomics is also lacking, in that it misses any 
post-translational modifications. Therefore, it could be argued that 
transcriptomics alone is not enough to understand how a virus is controlling a 
cell. Rather, proteomics - the study of the proteins present in cells - could 
provide a clearer picture of what is occurring. However, proteomics is much 
more expensive than transcriptomics and requires mass spectrometers. Hence, 
mechanistic studies are required along with transcriptomics analysis to decipher 
and fully trust the highlighted results.  
 
There are many different bioinformatics pipelines that can be used for 
the analysis of transcriptomic data, such as EdgeR and DeqSeq. These are 
pipelines that use count based tools, rather than CuffDiff2 that estimates 
expression at transcript-level resolution (Trapnell et al. 2013). The tool used in 
this thesis was CuffDiff2, commonly used for experiments with fewer replicates, 
as it produces lower numbers of false positives. Ideally, it would have been 
valuable to analyse the sequencing data using at least two separate pipelines 
and see which of the DE genes were highlighted in both and strengthen the 
conclusions drawn. However, the literature shows that there is usually 
corroboration between the different pipelines (Zhang et al. 2014), and so we 
increased the thresholds in order to select for more statistically significant DE 
genes.  
 
In order to validate the findings of the in silico pipelines, experiments in 
the literature have used qRT-PCR (quantitative Reverse 
Transcription Polymerase Chain Reaction) to quantify the RNA expression of a 
few selected genes within the cells (Ratinier et al. 2016; Liu et al. 2016). 
Quantifying the RNA expression could allow for a higher degree of confidence, if 
the results match up with those found through in silico analysis. However, it is 
not a necessary step nowadays with many tools in place to make the same 
arguments by cross-validation, which produces all of the standard statistics. It is 
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also discussed in this paper (Hughes 2009) how pursuit of validation can often be 
at the expense of a thorough evaluation of the key points of the results. 
Therefore, it was decided for the purpose of this thesis not to pursue the use of 
qRT-PCR, and instead use stricter thresholds for selecting the DE genes produced 
by the transcriptomic analysis in order to reduce the number of false positives 
DE genes identified.   
 
A lot of the data was gathered from observational studies, and while they 
do produce a lot of results and interesting areas for development, it would have 
been ideal to strengthen the claims and hypotheses of this thesis by including 
follow-up experiments. Techniques such as Western blotting could have been 
used to study the protein levels present within the cells. Western blotting would 
have been especially interesting as, has already been stated, transcriptomics 
only studies the transcripts present within a cell which doesn’t always relate 
directly to the proteins that are translated. Another technique that could have 
been used to investigate the results more mechanistically would have been 
reverse genetics. Different biologically active sites of the EIV proteins could 
have been targeted for mutagenesis, and the interactions of these viruses with 
the host response could have been studied. These kinds of experiments were not 
conducted for this thesis due to time constraints, as the setting up of the 
pipeline from cells to transcriptomics was time consuming. However, it is hoped 
that other members of the laboratory will continue this work. 
 
The work described in this thesis is a lot of the background work to set up 
a transcriptomics pipeline using equine cells and IAVs setting the scene for a 
project to continue on with studying different conditions in the E.Derm cells and 
using other culture systems.  
 
The ex vivo trachea organ culture technique is something that has been 
perfected in the Murcia lab. Some infections carried out using this system were 
included in Chapter 4, studying the presence of an IFN response within the 
tissue. However, it would be very interesting to study the infection of the organ 
cultures with IAVs using transcriptomics. The results of these experiments could 
be compared to those described in this thesis to see how realistic the in vivo 
gene expression results were. This thesis was used to primarily investigate 
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infections in E.Derm cells, as a proof-of-concept and to set up the 
transcriptomics pipeline for future work. The development of the pipeline 
included the set up of infections, the RNA extraction and sequencing, the testing 
of analyses tools for analysing the sequencing reads, and the writing of scripts 
and creation of figures to visualise the results. If there had been more time the 
next step could have been to sequence the infected ex vivo tracheal organ 
cultures. 
 
5.3. Final Conclusions 
This thesis describes the research that aimed to study influenza infection in a 
host-specific cell line, in order to establish how IAVs change the way they 
manipulate a host due to adaptation and evolution.  
 
The aims of this thesis consisted of: 
1. Characterization of an equine cell line for the in vitro study of EIV 
2. Explore equine host barriers to infection with different IAVs 
3. Determine the cellular response to infection between two evolutionary 
distinct equine influenza viruses of the same lineage using transcriptomics 
 
 I believe that all of the aims that were stated were achieved, although as 
has been discussed there remains future work to build upon the findings 
described here. Collectively, the research carried out in this PhD thesis provided 
significant tools for the in vitro study of EIV, and progress towards understanding 
how the evolution of an IAV can change how the virus manipulates the host cell. 
The characterization of an equine cell line, and how to study the specific host 
barriers and transcriptome, will be important tools for the future advancement 
of improving the basic knowledge of EIVs, and IAVs in general, and how they 
evolve over time to manipulate a host.  
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6.1. Materials 
6.1.1. Eukaryotic Cell Lines 
MDCK  Madin-Darby Canine Kidney Epithelial Cells (Source – ATCC) 
Maintained in Dulbecco’s Modified Eagle Medium supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. 
 
E.Derm Equine dermal cells (NBL-6) (Source – ATCC) 
Maintained in Dulbecco’s Modified Eagle Medium supplemented 
with 15% fetal bovine serum, 1% non-essential amino acids and 1% 
penicillin/streptomycin. 
 
293T  Human embryonic kidney cells (Source – ATCC) 
Maintained in Dulbecco’s Modified Eagle Medium supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. 
 
6.1.2. Viruses 
Where stated, reverse genetics viruses of equine viruses A/equine/Ohio/1/03 
(EIV/2003) and A/equine/Uruguay/1963 (EIV/1963) were used. The canine 
influenza virus A/canine/New York/dog23/2009 (CIV/2009) was also a reverse 
genetics virus. The isolate of virus A/equine/Uruguay/1963 was used in the 
infection of horse tracheal explants, rather than the reverse genetics virus. The 
virus A/ruddy shelduck/Mongolia/963V/2009 is an avian influenza virus isolate. 
 
6.1.3. Virus Passage History 
A/equine/Uruguay/1963:  
• Virus Isolate: Origin - NIMR collection. First isolated in eggs, number of 
further passages unknown. 
• Reverse Genetics Virus: Rescued by reverse genetics technique (Passage 
1), passaged in MDCK cells (Passage 2), titrated and passaged on MDCK 
cells to produce separate viral stocks (Passage 3). 
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A/equine/Ohio/1/03:  
• Virus Isolate: Origin - University of Kentucky. First isolated in eggs, 
number of further passages unknown. 
• Reverse Genetics Virus: Rescued by reverse genetics technique (Passage 
1), passaged in MDCK cells (Passage 2), titrated and passaged on MDCK 
cells to produce separate viral stocks (Passage 3) 
 
A/canine/New York/dog23/2009: 
• Virus Isolate: Origin – Cornell University. Unknown passage history. 
• Reverse Genetics Virus: Rescued by reverse genetics technique (Passage 
1), passaged in MDCK cells (Passage 2), titrated and passaged on MDCK 
cells to produce separate viral stocks (Passage 3) 
 
A/ruddy shelduck/Mongolia/963V/2009: 
• Virus Isolate: Origin - State Central Veterinary Laboratory (Mongolia). First 
isolated in eggs, and passaged another time in eggs. Further passaged 
three times in MDCK cells. 
 
6.1.4. Horse tracheas 
Horse tracheas were sourced from horses provided by the Animal Health Trust  
(AHT) and one horse was sourced from the Vet School, University of Glasgow 
(thanks to Nicola Kerbyson). 
 
6.1.5. Plasmids 
The full set of 8 plasmids for A/equine/Ohio/1/03 and A/canine/New 
York/dog23/2009 were a kind gift from Colin Parrish. The full set of 8 
A/equine/Uruguay/1963 plasmids were cloned by Alice Coburn, a fellow PhD 
student in the lab. 
 
The VSV glycoprotein plasmid was kindly provided by Brian Willett. 
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6.1.6. Reagents 
6.1.5.1. Tissue Culture 
• DPBS 
Dulbecco’s Phosphate-Buffered Saline 1X without calcium (Invitrogen, 
Catalogue Number: 14190-094) 
 
• NEAA 
100X MEM Non-Essential Amino Acids Solution (Invitrogen, Catalogue Number: 
11140-035) 
 
• 2X MEM 
MEM (Temin's modification) (2X), no phenol red (Life Technologies, Catalogue 
Number: 11935046) 
 
• TPCK 
Trypsin from bovine pancreas - TPCK Treated, essentially salt-free, 
lyophilized powder, ≥10,000 BAEE units/mg protein. (Catalogue Number: 
T1426-250MG) 
 
• DMEM  
Dulbecco’s modified Eagle’s medium High Glucose GLUAMax Pyruvate 
(Invitrogen, Catalogue Number: 31966021) 
 
• FBS  
(Fetal Bovine Serum), Life Technologies. 
 
• Trypsin 
Trypsin EDTA .05% 1X (Invitrogen, Catalogue Number: 25300-054) 
 
• NGS 
Normal Goat Serum, New Zealand Origin, Life Technologies (Catalogue 
Number 16210064) 
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• OptiMEM  
Opti-Minimum Essential Medium (Life Technologies, Catalogue Number: 
11058021)  
 
• Poly I:C 
Polyinosinic-polycytidylic acid (HMW, 10mg) (Invivogen, Cat Code: tlrl-pic) 
 
• BSA 
Bovine Albumin Fraction V (7.5% solution) (Thermo Fisher Scientific, 
Catalogue Number: 15260037) 
 
• IFN-α 
Human Universal Type I Interferon (PBL Assay Science, Catalogue 
Number: 11200-2-PBL) 
 
• RPMI 
Roswell Park Memorial Institute 1640 medium (Invitrogen, Catalogue Number: 
21875-034) 
 
•  Penicillin/Streptomycin  
Invitrogen, Catalogue Number: 15140-122 
 
• L-glut 
L-glutamine (Invitrogen, Catalogue Number: 25030-024) 
 
• Fungizone  
Gibco™ Amphotericin B (Invitrogen, Catalogue Number: 15290026) 
 
• Polybead® Carboxylate Blue Dyed Microspheres 1.00µm 
Polysciences Inc., Cat Number: 19120, 15ml 
 
6.1.5.2. Fixing and staining solutions 
• Formalin solution neutral buffered, 10% (diluted to 1% or 4% in PBS, as 
required) (Sigma-Aldrich, Catalogue Number: HT501128-4L) 
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• TrueBlue Peroxidase Substrate (200ml) (Insight Biotechnology LTD, 
Catalogue Number: 5510-0030) 
• DAKO System - HRP (DAB+) (Agilent, Product Number: K401011-2) 
• Acetone Solution (diluted to 80% in distilled water) (VWR, Catalogue 
Number: 20066330) 
• Phosphate Buffered Saline tablets (Fisher Scientific, Catalogue Number: 
1282-1680) 
 
6.1.5.3. Transfection reagents 
• TransIT-LT1 Transfection Reagent (Mirus, Catalogue Number: MIR 2300) 
 
6.1.5.4. Virus plaque assay overlay 
• Avicel overlay 1.2% (w/v) 
Avicel RC/CL, Microcrystalline cellulose & Sodium carboxymethylcellulose 
was mixed for a final concentration of 1.2% in 500ml of distilled water. 
Autoclaved and stored at room temperature until use. Diluted in a 1:1 
ratio with 2XMEM, and 1µg/ml of TPCK-trypsin was added prior to use in 
plaque assays. 
 
6.1.5.5. RNA Extraction and Analysis 
• Trizol Reagent (Invitrogen, 15596026) 
• Agilent RNA Pico Kit (Agilent Technologies, Catalogue Number: 5067-1513) 
• Qubit® RNA BR Assay Kit  (Life Technologies; Reference: Q10210) 
• RNeasy Mini Kit (Qiagen; Catalogue Number: 74104)  
• RNase-Free DNase Set (Qiagen; Cat Number: 79254) 
• RNaseZap® RNase Decontamination Solution (Ambion, Catalogue Number: 
AM9782) 
• RNase-free Microfuge Tubes (1.5 mL) (Thermo Fisher Scientific, Catalogue 
Number: AM12400) 
• TruSeq Stranded mRNA Library Prep Kit High Throughput (RS-122-2103) 
• NextSeq® Sequencing System  
• NextSeq® 500/550 High Output Kit v2 (75 cycles, FC-404-2005)  
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6.1.5.6. Antibodies 
Primary Antibodies 
• Anti-HA (A kind gift from Colin Parish, dilution 1:2000) 
• Polyclonal rabbit anti-NP (Genescript, dilution: 1:500) 
• Monoclonal mouse anti-NP, Clone HB65 (European Veterinary Laboratory, 
dilution 1:1500) 
• Monoclonal mouse anti-Mx1 (Mab 143 anti-Mx1, dilution 1:600 (IF) and 
1:200 (IHC)), kindly supplied by Georg Kochs 
 
Secondary Antibodies 
• Anti-rabbit Alexa Fluor 488, Catalogue Number: ab150077 (Abcam, 
Dilution 1:2000 for IF and FACS) 
• Anti-mouse Alexa Fluor 488, Catalogue Number: A-11001 (Abcam, Dilution 
1:2000 for IF and FACS) 
• HRP anti-mouse 
• Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed) (Bio-Rad, Catalogue 
Number: STAR13B) 
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6.2. Methods 
6.2.1. Cell Culture 
Cell monolayers were cultured and maintained in 25, 75 or 150cm2 tissue culture 
flasks. When cell monolayers reached 90% confluence, they were washed with 
DPBS and treated with Trypsin EDTA until the cells detached (37°C for all cell 
lines, except E.Derm which were kept at room temperature). Detached cells 
were re-suspended in media containing FBS to stop the action of the Trypsin 
EDTA and centrifuged at 1000 rpm to pellet cells. Pellet was re-suspended in 
appropriate media. For general maintenance cells were split at a ratio of 1:10, 
except for E.Derm cells, which were always split 1:2. All cells were kept in a 
humidified atmosphere with 5% CO2 at 37°C. 
 
6.2.2. Influenza Reverse Genetics 
293T cells and MDCK cells were plated in six-well plates one day before 
transfection using a 2:1 ratio of 293T to MDCK cells. The cell co-cultures were 
transfected with 300ng of each of eight plasmids containing all the genomic 
segments of the influenza virus to be rescued. Transfections were performed 
using TransIT-LT1 according to the manufacturer's instructions. 7.5µl of TransIT-
LT1 transfection reagent per 2.5µg of DNA was mixed, incubated at room 
temperature for 30 minutes, and added to the cells. A day later, media was 
replaced with DMEM containing 0.3% bovine serum albumin (BSA) and 1µg/ml of 
TPCK trypsin. After 72 hours of incubation, supernatants were collected and 
clarified by low-speed centrifugation, aliquoted, stored at −80°C and titrated. 
This was called termed as passage 0 – P0. The reverse genetics virus was then 
subsequently passaged on MDCK cells to grow the virus to a high titre. 
 
6.2.3. Experimental Infections 
Unless otherwise stated cells were inoculated with virus diluted in infectious 
media for the required MOI and placed for 1 hour at 37°C. The inoculum was 
then washed off and replaced with either fresh infectious media or the 
appropriate regular media. Plates were then placed at 37°C for 60 minutes to 
allow viral entry, after which the inoculum was washed off and replaced with 
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fresh regular media. 
 
6.2.4. Virus quantification by plaque assays 
Viral titres were determined by standard plaques assays on MDCK cells and 
revealed by immunostaining of plaques. Cells were plated in 48-well plates and 
infected upon confluence 18-24 hours later. The inoculum was washed with DPBS 
after two hours of incubation and the cells were then overlaid with a 1:1 mix of 
2XMEM and Avicel (1.2% w/v Stock) supplemented with TPCK trypsin to a 
concentration of 1µg/ml. Two days after infection cells were fixed in 80% 
acetone solution for at least 10 minutes at room temperature and then 
permeabilised with 1% Triton X100 + PBS for 10 minutes at room temperature. A 
mouse monoclonal anti influenza A NP antibody and Rabbit F(ab')2 anti Mouse 
IgG:HRP (Human Adsorbed)  were used as primary and secondary antibodies, 
respectively. To visualize the infected cells, True Blue peroxidase substrate was 
added, and was stopped less than 10 minutes of incubation once colour had 
developed. Viral titres were calculated by counting blue plaques. Titres were 
expressed as log10 PFU per millilitre.  
PFU/ml = P/(D x V)   P = Plaque number 
      D = Dilution factor of the well counted 
      V = Volume of diluted virus added to the well 
 
Virus titrations throughout this thesis are affected by a methodological error,. 
This error was at the stage of dilution of the virus to be titrated where a 
multichannel was used to dilute viruses in 96 well plates. Instead of tips being 
changed in between every dilution, tips were changed between row 4 and 5. 
This means that virus will have been carried over between wells, and titres will 
be overestimated. As stated by Chase and Hoel, “errors of this magnitude can 
result in dramatic increases in the variation of the estimate of the initial 
concentration” (Chase & Hoel 1975). 
 
Regrettably, it was not possible to repeat these experiments in the time 
available and, because the degree of systematic error might vary, the ability to 
make quantitative comparisons between these data is limited. However, it is 
still possible to describe changes in qualitative terms. 
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6.2.5. Preparation of working viral stocks 
All viruses used in this study were grown in MDCK cells. Cells were infected at an 
MOI of 0.001 PFU/cell in infectious media containing DMEM, with no FBS, 0.3% 
BSA and 1 µg/ml of TPCK trypsin.  Cells were incubated at 37°C for 1 hour, and 
then washed with DPBS before replacing with infectious media and incubated at 
37°C and 5% CO2. Cells were constantly checked for Cytopathic Effects (CPE) 
and when this reached 80% of dead cells (usually ~36 hours post-infection) the 
supernatant from the flasks were removed and centrifuged at 1,000 rpm for 5 
minutes at room temperature to pellet any cell debris. The clarified supernatant 
was then stored in 0.2 ml aliquots at -80°C.  
 
Each virus stock was grown independently so that each independent repeat 
experiment was carried out with a new virus stock, allowing for the observation 
of differences in viral quasispecies. This method of virus preparation was 
considered especially important when carrying out transcriptomic experiments, 
in case a certain transcriptome was due to a particular viral quasispecies.   
 
6.2.6. Virus infection 
To study viral growth kinetics, cells were seeded in 12-well plates at 
2×105cells/ml. 18-24 hours later the cells were infected with 250µl virus 
inoculum calculated at the desired viral MOI and diluted in infectious media. 
After an adsorption period of 1 hour at 37°C, virus inoculum was removed and 
the cells were washed with DPBS. At desired time points supernatant was 
collected and cells were harvested for FACS analysis. Viral titres were 
determined by plaque assay on MDCK cells as described. 
 
6.2.7. Immunofluorescence 
Cells were seeded at a density of 2×105cells per well of a 12-well plate 
containing 30mm glass coverslips.  18-24 hours later the cells were infected with 
virus at the desired MOI diluted in infectious media. At the required time-points 
the cells were fixed for 30 minutes at room temperature with 4% formalin 
diluted in DPBS. Cells were then permeabilised for 10 minutes at room 
temperature in 1% Triton X100 + PBS. Cells were then incubated for 2 hours with 
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the primary antibody at the required dilution and then washed three times in 
DPBS to get rid of any unbound antibody. Cells were then incubated for 1 hour in 
the dark with the secondary antibody and washed again using DPBS. The 
coverslips were then mounted onto slides using VECTASHIELD mounting solution 
and stored at 4°C until imaging using a Zeiss 710 Confocal Microscope. 
 
6.2.8. Rescue of VSV-ΔG-GFP virus 
293T cells were grown in a 10cm2 dish for 60-80% confluence and a transfection 
mix of 200ul Opti-MEM, 2µg of plasmid containing the missing VSV glycoprotein 
gene, and 6µl of Trans IT-LT was prepared and incubated at room temperature 
for 30 minutes before being added to the cells in a drop-wise manner. The next 
morning the transfection was washed off and the plate was incubated for 
another 36 hours. After, 293T transfected cells were infected with a previous 
stock of VSV-ΔG-GFP virus and incubated for a further 16 hours. Supernatant was 
removed and passed through a 0.45µm filter. VSV-ΔG-GFP virus stock was 
titrated on E.Derm cells by serially diluting the virus and infecting cells, infected 
cells were measured by Fluorescence-Activated Cell Sorting (FACS). 
 
6.2.9. IFN Competence Assays 
Cells were seeded on a 48-well plate and 18-24 hours later treated with 
increasing concentrations of Universal IFN-α for 4 hours and 24 hours before 
being challenged with VSV-ΔG-GFP. Cells were treated for 4 and 24 hours with 
increasing concentrations of high molecular weight Poly I:C and then challenged 
with VSV-ΔG-GFP. 16 hours after infection with VSV-ΔG-GFP the cells were fixed 
in 1% formalin overnight and were counted using the Guava FACS machine to 
calculate the percentage of infected cells expressing GFP.  
 
6.2.10. FACS Staining 
Cells were fixed in 1% formalin at 4°C overnight. After the cells were 
permeabilised with 1% Triton X100 for 10 minutes, blocked in 10% NGS + PBS for 
1 hour, incubated with primary antibody for 2 hours and then washed 3 times 
with DPBS. The secondary antibody was incubated for 1 hour and washed 
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another further 3 times before being fixed again in 1% formalin. Antibodies were 
diluted in 10% NGS + PBS. Cells were then quantified using the Guava FACS 
machine. 
 
6.2.11. Ex-Vivo Experimental Work 
Explant preparation 
The whole trachea was aseptically collected upon euthanasia and transported in 
culture medium consisting of a 1:1 mixture DMEM and Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with penicillin, streptomycin (50 
µg/ml, L-glutamine and fungizone (2.5 µg/ml). The tracheas underwent 6 
washes over a period of 4 hours in pre-warmed culture medium, being kept at 
37°C in a 5% CO2–95% air mixture in a humidified incubator. Extra connective 
tissue on the cartilage was removed and the tracheas were opened up and cut 
into six strips that were each cut into square explants of approximately 0.5cm by 
0.5cm. The explants were then placed on square pieces of sterile filter paper on 
top of agarose plugs in 6-well plates mimicking the air interface found in the 
respiratory tract of the living animal, and kept for up to seven days in 5% CO2 
and 37°C in a humidified incubator. 
 
Experimental infections 
Explants were infected with a dose of 200 PFU 24 hours after explant 
preparation (designated as time 0). Culture medium was used for mock-infected 
explants. Inoculated explants were sampled for, histology and viral replication 
at 6 hours and every 24 hours post-infection for five days. 
 
Quantification of virus present in infected explants was carried out by immersion 
of the explants in 0.5 ml of sterile DPBS followed by vortexing for at least five 
minutes. The supernatant was then quantified by plaque assays as described 
above. 
 
Interferon Assay 
For the IFN assay of horse explants, inoculation with Universal Type I IFN Alpha 
was carried out by placing increasing concentrations of Universal IFN, diluted in 
10µl of DMEM, onto the explants for 24 hours. 
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6.2.12. Immunohistochemistry 
Explants were fixed in 10% (v/v) buffered formalin and paraffin embedded. 
Subsequently, 4µm paraffin sections were cut and tissue sections were 
deparaffinised and hydrated using standard procedures. Antigen retrieval was 
performed using citrate buffer followed by pressure cooker heating. In order to 
quench endogenous peroxidase, sections were permeabilised with 1% Triton x100 
for 10 minutes, and then incubated in a peroxidase blocking buffer for 10 
minutes. Sections were incubated overnight at 4°C with either of the following 
primary antibodies diluted in 10% normal goat serum: polyclonal rabbit anti-NP 
or monoclonal mouse anti-Mx1. Immunohistochemistry was performed with DAKO 
supervision system, which included an HRP labelled polymer that is conjugated 
to secondary antibodies - either an anti-mouse of anti-rabbit secondary 
depending on primary antibody used, and slides were counterstained with 
Mayer’s haematoxylin. Histological images were taken using cell^D software 
(Olympus).  
 
6.2.13. Experimental Work Involving Transcriptomics 
6.2.13.1. RNA Extraction 
Add 1ml of TRIzol®Reagent to the well of a 12-well plate and pipette up and 
down several times to lyse cells. Incubate the homogenized sample for 5 minutes 
at room temperature and then add 0.2 mL of chloroform per 1mL of 
TRIzol®Reagent used for homogenization. Shake tube vigorously by hand for 15 
seconds and then incubate for 2–3 minutes at room temperature. Centrifuge the 
sample at 12,000 × g for 15 minutes at 4°C. Carefully remove the aqueous phase 
of the sample and avoid contaminating with any of interphase or organic layer. 
Then add 230ul of 100% ethanol to aqueous phase and mix and add to a column 
from the RNeasy Mini Kit and centrifuge for 30 seconds at maximum speed. 
Perform one wash with RW1 buffer from RNeasy Mini Kit and at this point for the 
complete removal of DNA from sample, use the RNase-Free DNase Set in 
conjunction. After the DNase I step, continue with the washing steps of the 
RNeasy Mini Kit. Finally elute in 30ul of nuclease free water. 
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6.2.13.2. Qubit 
The Qubit® 2.0 Fluorometer (Life Techonologies) is used as a precise way to 
measure RNA concentration within a sample. The Qubit® RNA BR Assay Kit was 
used as per the manufacturer’s instructions. 
 
6.2.13.3. Bioanalyser 
Before sending the samples to sequence, the Agilent 2100 Bioanalyzer was used 
for the analysis of RNA purity by separating the nucleic acid fragments based on 
their size by electrophoresis. The Agilent RNA Pico Kit was used as per the 
manufacturer’s instructions. Only samples with a RNA Integrity Number (RIN) 
above or equal to 8 were sequenced. 
 
6.2.13.4. Sequencing 
Each sample (Mock, IFN-α, EIV/1963 and EIV/2003) was set up independently 
three times, and sequenced on separate Illumina runs, with 24 samples being 
carried out in total. On average, ~28 million reads/sample was generated, Phred 
quality >30 (A Phred quality score is a measure of the quality of the 
identification of the nucleobases generated by automated DNA sequencing). 
Libraries for the samples were prepared using TruSeq Stranded mRNA Library 
Prep Kit High Throughput (RS-122-2103). Each library was made from 300ng total 
RNA /per sample and NextSeq® Sequencing System was used, with each 
sequencing run containing 16 Libraries. NextSeq® 500/550 High Output Kit v2 (75 
cycles, FC-404-2005) Cartridges were used. 
 
 
6.2.13.5. Sequencing quality and assembly 
Bioinformatics analysis was performed using the FastQC software 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc) to check the RNA-
Seq reads quality. Kraken (REF) was used to check the contamination of samples. 
TopHat2 is a fast splice junction mapper for RNA-Seq reads. It aligns RNA-Seq 
reads to mammalian-sized genomes using the ultra high-throughput short read 
aligner Bowtie2, and then analyses the alignment results to identify splice 
junctions between exons. In the present research, we align the short reads to 
the Equus caballus genome (Equ Cab 2), downloaded via Ensembl (Ensembl 
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genome browser 84) April 2016.  In total, 89.4% of the sequence reads assembled 
to the reference genome. 
 
6.2.13.6. Differential expression and pathway analysis 
CuffDiff2 is a program in the Cufflinks package (v2.2.1). It adopts an algorithm 
that controls cross-replicate variability and read-alignment ambiguity by using a 
model for fragment counts based on a beta negative binomial distribution. It can 
identify differentially expressed transcripts and genes, differential splicing and 
promoter-preference changes, which returns far more statistically significant 
differentially expressed genes than microarray analysis. CuffDiff2 was used to 
identify Differentially Expressed (DE) genes (genes with Benjamini Hochberg P-
value ≤ 0.05 were considered significant).  
 
6.2.13.7. Data Analysis 
Transcriptomics data was analysed using Ingenuity Pathway Analysis (IPA) 
(https://analysis.ingenuity.com/) software to visualise pathways and produce 
figures. R Version 3.2.3 (RTeam 2017) was used to produce some figures, as was 
GraphPad Prism (Anon n.d.). 
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